Document:

Exhibit 10.9

 

OFF-TAKE AGREEMENT

 

THIS
OFF-TAKE AGREEMENT (this “Agreement”), dated 3rd August 2020, (the “Effective Date”)
is made and entered into by and between Medcan Ltd,a company incorporate in the Republic of Malta with registration number C 73431
(“Medcan”) and Bophelo Bio Science and Wellness Pty Ltd, a company incorporated in the Kingdom of Lesotho with the
registration number 2018/62924 (“BOPHELO”), both of whom are hereinafter collectively referred to as the “Parties”
and any one of which shall be referred to as a “Party” as the context may require. This Agreement shall apply
to each and every delivery and sale of Bulk Extract (defined in “DEFINITIONS” below) by BOPHELO to Medcan and shall constitute
the entire agreement between the Parties with respect to the purchase and sale of Bulk Biomass.

 

DEFINITIONS:

 

In this Agreement,
unless the context clearly indicates a contrary intention, the following expressions shall bear the following meanings and related expressions
shall bear corresponding meanings:

 

“Bophelo’s
nominated account” – [Account Name - Bophelo Bio Science & Wellness; Account No. - l l 990043908; Nedbank Mafeteng
Branch; Branch Code - 390461; Swift Code - NEDLLSMX], or such other bank account as BOPHELO may nominate on written notice of not
less than 7 days to Medcan;

 

“Bulk Biomass”  – means both
Flower and Trimmings, each of various grades (of potency, strains and other qualities) to be purchased by Medcan hereunder;

 

“business day” – means any day other
than a Saturday, Sunday or official public holiday in Lesotho;

 

“Commencement
of Bulk Biomass Processing” – means the commencement of drying, trimming, and processing operations;

 

“Cultivation
Facility” – mean the greenhouses, hoop-houses and/or other indoor or outdoor cannabis cultivation facilities
designed, built and operated by BOPHELO for the cultivation of cannabis and production of cannabis crops by or on behalf of BOPHELO
in compliance with such standards for the cultivation and collection of cannabis crops as may be imposed in terms of the
requirements of the various markets to which the products produced by BOP HELO are to be exported (the relevant standards
hereinafter collectively referred to as “Agricultural Practices Standards” );

 

“EFT” 
 – electronic funds transfer, being a transfer of funds between bank accounts on the internet (free of set off, bank charges
levied by the paying party’s bank or deductions of any nature whatever);

 

“Flower” – dried
cannabis flower harvested from female cannabis plants, packed in 1 kilogram bags ready for sale;

 

    Page 1 of 14

     

    

 

“Prime
Rate” – the rate of interest publicly quoted by Nedbank Lesotho, from time to time, as being its prime rate of
interest (expressed as a nominal annual compounded monthly in arrear rate), calculated on a 365 day
a year basis, irrespective of whether or not the year is a leap year and prima facie proved, in the event of there being a dispute
in relation thereto, by a certificate signed by any manager of the aforesaid bank (whose appointment, qualification or authority
need not be proved);

 

“Property”
 – the land situated at Ts'akholo, Mafeteng, Kingdom of Lesotho and having the GPS co-ordinates latitude 29°39’
46.28”S and longitude 27°9’ 36.01”E;

 

“Specified
Volume” – 10,000 kilograms of Bulk Biomass;

 

“Trimmings” – any
extraneous plant matter harvested as a by-product of trimming cannabis flower, packed in 1 kilogram bags available for sale;

 

Where any term is defined
within the context of any particular clause of this Agreement, the term so defined, unless it is clear from the clause in question that
the term so defined has limited application to the relevant clause, shall bear the meaning ascribed to it in terms of the particular clause
for all purposes in terms of this Agreement, notwithstanding that the term has not been defined in this Definitions clause.

 

RECITALS:

 

WHEREAS, Medcan is a private limited liability company with registered address at Level 4, the Penthouse, Suite 2, Ewropa
Business Centre, Triq Dun Karm, Birkirkara, BKR 9034, Malta and with the objects of the company
including, inter alia, the importation, preparation and distribution of marijuana for medical use by patients in Malta and to this end,
Medcan intends on importing the Bulk Biomass purchased from BOPHELO under this Agreement;

 

WHEREAS, BOPHELO
holds a Prohibited Drug Operator license authorizing it to engage in the business of cannabis cultivation, manufacturing of cannabis  products
and export of cannabis and cannabis products, and is in good standing with all relevant and necessary local and national licensing authorities
in the Kingdom of Lesotho;

 

NOW, THEREFORE,
in consideration of the foregoing recitals, which said recitals are incorporated herein by this reference, and the mutual covenants
and conditions hereinafter contained, the Parties agree as follows:

 

BOPHELO agrees
to sell, and Medcan agrees to buy Bulk Biomass that BOPHELO produces from the cannabis cultivated on the initial 5 hectares of the Property
in the Cultivation Facility;

 

l. Contract Term: The term of this Agreement shall, subject to any termination in terms of section 8, be for a period commencing
on the Effective Date and ending on the date being the earlier of (i) the date on which Medcan has purchased the full Specified Volume
from BOPHELO; or (ii) the 7th anniversary of the
Effective Date (“the Final Date”).

 

	2.	Delivery: 

 

	2.1	BOPHELO agrees to deliver to Medcan
                                   the Specified Volume, unless otherwise agreed in writing by both Parties, of Bulk Biomass each week,
                                   beginning one (1) week after Commencement of Bulk Biomass Processing (the “First Delivery
                                   Date”). BOPHELO shall thereafter give Medcan not less than 5 days’written notice
                                   in advance each time that a delivery will be ready for collection in terms of section 2.2.

 

    Page 2 of 14

     

    

 

	2.2	The Bulk Biomass shall be delivered Ex Works (as
                                            such term is defined in INCOTERMS 2010) and Medcan will take delivery of the Bulk Biomass
                                            Ex Works subsequent to customs clearance in a port in Malta (“Clearance”)
                                            and BOPHELO will, procure the transport of the Bulk Biomass by a cannabis transport operator
                                            licensed as such in terms of the Drugs of Abuse Act, 2008 of Lesotho to an international
                                            airport in Lesotho or South Africa, or a seaport in South Africa (each such location, a “Port”)
                                            as agreed upon by both Parties and shall take such steps as may be required for clearing
                                            the Bulk Biomass for export, subject to Medcan having, with at least 30 (thirty) days advance
                                            notice, provided (i) correct and comprehensive instructions to BOPHELO as regards any requirements
                                            (including, but not limited to approved strains, packing and labelling specifications and
                                            correct licenses in respect of the country of import) which the Bulk Biomass or any particular
                                            Batch (as such term is defined in section 2.4) need to comply with; and (ii) a copy of all
                                            relevant documentation, including specifically documentary proof of the country of import's
                                            consent to importation as required for purposes of BOPHELO obtaining the relevant export
                                            permit, in order to enable the Batch to be legally and validly exported via the designated
                                            Port to the port of destination. Notwithstanding anything herein contained, BOPHELO shall
                                            not incur any liability of any nature whatsoever, whether to Medcan or any third party, for
                                            any failure to have the Bulk Biomass or any particular Batch cleared for export due to incorrect
                                            instructions having been provided to BOPHELO by Medcan willingly and knowingly in this regard
                                            or the Bulk Biomass or any particular Batch not meeting the legal requirements for import
                                            and Clearance and Medcan hereby indemnifies and holds BOPHELO harmless against any claim
                                            made against BOPHELO in this regard. Medcan shall be responsible for (i) all other tasks
                                            through clearing the Bulk Biomass through customs in the importing country; and (ii) receiving
                                            and transporting the Bulk Biomass after it has been so transported for Clearance. Medcan
                                            may perform the foregoing actions, or appoint a properly licensed third party to do so on
                                            Medcan’s behalf. All Bulk Biomass will be free and clear of any liens, claims and encumbrances.

 

	2.3	Notwithstanding the terms of delivery being Ex Works, BOPHELO agrees
                                   to pay an amount equal to 50% of the actual costs incurred by Medcan in the process of landing a Batch
                                   at the import destination, including, inter alia, transport costs, export and import duties,
                                   customs and handling fees, but excluding costs of insurance (“landing costs”), provided
                                   that BOPHELO’s contribution to landing costs shall never exceed an amount equal to 5% of the
                                   total amount paid by Medcan to BOPHELO for the Batch in terms of section 6.l. BOPHELO shall pay such
                                   costs to Medcan upon presentation of an invoice setting forth the costs incurred as line items and
                                   shall, if so required by BOPHELO, furnish documentary proof of the costs so incurred.

 

	2.4	Risk of loss of the Bulk Biomass shall pass to Medcan
                                            upon completion of delivery, namely, Clearance, by BOPHELO Ex Works at the Extraction Facility.
                                            Title to and ownership of the Bulk Biomass shall pass from BOPHELO to Medcan against payment
                                            by Medcan to BOPHELO in terms of section 6. BOPHELO will deliver each batch of Bulk Biomass
                                            with a Certificate of Analysis, including residual, pesticide and potency results, from an
                                            independent, properly licensed and credentialed cannabis analytical testing laboratory (“Compliant
                                            Laboratory”) in Lesotho or South Africa (a “COA”), indicating that
                                            each batch of Bulk Extract meets the Specifications (as such term is defined below). All
                                            Bulk Biomass packaged under the same COA is hereinafter referred to as a “Batch”.
                                            Medcan shall at any time and from time to time, at its cost, be entitled to submit the Bulk
                                            Biomass to any compliant laboratory outside Lesotho or South Africa for analysis.

 

    Page 3 of 14

     

    

 

	2.5	If BOPHELO has notified Medcan in accordance with section 2.1 that a Batch is ready
for delivery and Medcan has for any reason whatsoever (other than Medcan’s legitimate rejection of the relevant Batch in accordance
with the provisions of section 3(b)) failed to take delivery of such Batch Ex Works within 15 days from the date of the notice contemplated
in section 2.1, Medcan shall be liable to make payment to BOPHELO for such Batch in accordance with the provisions of section 6 as if
Medcan had taken title to and delivery thereof. BOPHELO shall, at Medcan’s risk, store such Batch in a secured, temperature-controlled
storage area for Clearance, provided that –

 

	2.5.1	if Medcan fails to make payment for the relevant batch within the 15 day period aforementioned,
BOPHELO shall be entitled to dispose of or destroy the Batch as it deems fit;

 

	2.5.2	if Medcan has made payment to BOPHELO for the relevant Batch, but has failed to accept
delivery thereof within a period of 6 months from the date of the notice contemplated in section 2.1, BOPHELO shall be entitled to dispose
of or destroy the Batch as it deems fit, and BOPHELO shall,
if it has sold any Batch as contemplated above, pay to Medcan the proceeds received from such sale, less reasonable storage costs and
any costs incurred by BOPHELO in the course of selling and delivering the relevant Batch to the purchaser in question. BOPHELO shall
promptly return any payments made by Medcan for such Batches as are subsequently found at delivery not to be accompanied by a valid COA,
or for which the accompanying COA indicates a failure to satisfy the Specifications.

 

	2.6	If by the Final Date Medcan has not purchased the total Specified
Volume from BOPHELO under this Agreement, Medcan undertakes to pay to BOPHELO within 7 business days of the Final Date an amount equal to Z calculated in accordance with the following formula –

 

Z = (A-B) x P

 

where

 

Z represents the amount payable;

 

A represents the Specified Volume;

 

B represents the actual volume of Bulk
Biomass which Medcan has purchased from Bophelo as at the Final Date; and

 

P represents the then prevailing market
rate per gram of Bulk Biomass as determined in accordance with section 6.1.

 

    Page 4 of 14

     

    

 

For the avoidance
of doubt it is recorded that if sufficient Bulk Biomass has not been produced to meet the Specified Volume by the Final Date, save where
such failure is as a result of a breach or negligence by BOPHELO of this Agreement, BOPHELO shall have no liability of any nature whatsoever
arising from such failure and Medcan hereby indemnifies and holds BOPHELO harmless against any claim made against BOPHELO in this regard.

 

	2.7	As holder of the Prohibited Drug Operator license under the
Drugs of Abuse Act, 2008, BOPHELO shall be responsible to procure and import all cannabis seeds required for purposes of cultivating
cannabis at the Cultivation Facility. Medcan shall at all times and from time to time during the term of this Agreement give BOPHELO
written instructions as to the strains of the seeds to be purchased by BOPHELO for this purpose. BOPHELO shall not incur any liability
of any nature whatsoever, whether to Medcan or any third party, if it has procured seeds on the instructions of Medcan and such seeds
turn out to be seeds of a strain(/s) of cannabis plant not permitted under the import authorisations of the territories to which Medcan
intends to sell the Bulk Biomass produced from plants cultivated from the seeds. Medcan hereby indemnifies and holds BOPHELO harmless
against any claim made against BOPHELO in this regard and all loss and damages which BOPHELO may suffer as a result of Medcan having
provided incorrect instructions for the seeds to be procured and imported by BOPHELO.

 

3. Packaging of Bulk Biomass:

 

	(a)	BOPHELO will deliver Bulk Biomass to Medcan in containers complying with the applicable Agricultural
                                                  Practices Standards (“Containers”) or as otherwise agreed in writing between the Parties; BOPHELO shall not
                                                  co-mingle different Batches in the same Containers. BOPHELO will pre-fill each Container with up to 1000 grams of Bulk Biomass,
                                                  before further packaging each Batch in accordance with the applicable Agricultural Practices Standards for delivery to Medcan. Each
                                                  Batch will be packaged, labelled, marked and shipped in its own set of Containers, segregated from other Batches, in a commercially
                                                  reasonable manner, and in accordance with the applicable Agricultural Practices Standards and all applicable laws, rules and
                                                  regulations of the importing territory timely identified to BOPHELO by Medcan in writing. Medcan shall be responsible for
                                                  communicating to BOPHELO, in writing, all requirements and specifications with which a Batch needs to comply in order to ensure it
                                                  is cleared for export and is capable of being imported to the relevant importing territory. BOPHELO shall not incur any liability of
                                                  any nature whatsoever, whether to Medcan or any third party, for any failure to have a Batch cleared for export due to incorrect
                                                  requirements and/or specifications having been communicated to BOPHELO by Medcan in this regard and a Batch accordingly not meeting
                                                  the legal requirements for importation into the importing territory, and Medcan hereby indemnifies and holds BOPHELO harmless
                                                  against any claim made against BOPHELO in this regard. BOPHELO will weigh each empty Container independently before filling and
                                                  include the exact weight of the empty Container on its label.

 

    Page 5 of 14

     

    

 

	(b)	All Bulk Biomass supplied by BOPHELO is subject to
                                            Medcan’s inspection and acceptance or rejection at the Cultivation Facility prior to BOPHELO’s
                                            delivery Ex Works. A Compliant Laboratory shall conduct an inspection of each Batch before
                                            it is loaded into the relevant transport vehicle. If this inspection
                                            reveals that the Batches being delivered do not conform to the requirements set forth in
                                            sections 2, 3 or 4, Medcan will forthwith advise BOPHELO of such non-compliance in writing
                                            and shall be entitled to reject any Batch which it considers non-compliant. If a batch is
                                            rejected, BOPHELO shall at its election be entitled to remediate such Batch or otherwise
                                            dispose of it as it deems fit. Any Batch so rejected (and not remediated) shall be retained
                                            by BOPHELO and excluded for purposes of determining the weight of the relevant delivery
                                            made. All Bulk Biomass shall be weighed upon delivery, prior to being loaded on the relevant
                                            vehicle for transport, and the weight (hereinafter “the Delivery Weight”)
                                            shall be recorded, a copy of which recording shall be given to BOPHELO and an original shall
                                            be retained by Medcan. For the sake of clarity, the Parties agree that the weight of the
                                            empty Containers will not be included in the weight of the Bulk Biomass.

 

4.
Procured Cannabis Specifications: BOPHELO shall ensure that all Bulk Extract delivered to Medcan complies with the Specifications
set forth in subparagraphs (a) and (b) of this section 4 as follows:

 

		(a)	The levels of residual
                                            pesticide, microbes, foreign material, mycotoxins, heavy metals and other impermissible chemicals
                                            in each Batch must be at or below the maximum levels set forth in the applicable Agricultural
                                            Practices Standards of the importing territory identified by Medcan, as the same may be amended
                                            from time-to-time by agreement in writing between the Parties (“Chemical Specifications”).

 

		(b)	Each Batch must provide a total THC
                                            concentration at least twelve percent (12%) (its “Total THC Concentration”).
                                            Total THC Concentration shall be verified be ensuring that each one gram of Bulk Extract
                                            would yield a combined total of at least 120 milligrams of THC and THCA, using the following
                                            formula: Total THC Concentration (mg/g) = (THCA concentration (mg/g) x 0.877) + THC concentration
                                            (mg/g) (“Potency Specifications”, and together with the Chemical Specifications,
                                            the "Specifications").

 

	5.	Pricing and Payment Terms:

 

	5.1	Medcan will pay BOPHELO prevailing market rates (the “Price”) calculated on the basis of a Price per gram based on the Delivery Weight, which Price shall be payable
                                  upon delivery of the Bulk Biomass Ex Works as set forth in section 2. The Price for each Batch shall
                                  be determined as follows –

 

	a)	the Price shall always be determined on the basis that Medcan shall seek to sell the
Batch at the highest value achievable in the market, the average price for Bulk Biomass for 2020 and 2021 will be $3.00 USD per gram;

 

	b)	within 3 days of the date of the notice from BOPHELO as contemplated in section 2.1,
the Parties shall endeavour to agree on the Price for the relevant Batch, and shall record such price in writing between them;

 

    Page 6 of 14

     

    

 

	c)	if the Parties fail to agree on the Price in the period contemplated in section 6.1(b), the Price (always
subject to the principle in section 6.1(a)) shall be obtained from referencing the price per gram for such product as reflected in the
most as published by Canaccord Genuity Group Inc (“Cannacord”); provided that if Canaccord no longer publishes such report
or index publicly and the parties are unable to instruct Canaccord to prepare or provide such a report for their specific purpose, the
Price shall be equal to the average of the wholesale price per gram as applied by the 5 biggest international cannabis trading companies
by market capitalisation (“average wholesale price”). If for any reason the parties are unable to obtain the necessary information
to determine the average wholesale price at any point in time, the parties agree that the price will be determined by an independent expert
in international cannabis trading (“the expert”), such expert to be a person as nominated by the head of the cannabis practice
cluster of the firm of Aird & Berlis LLP, Toronto. The expert shall be instructed to determine the average wholesale price based on
his/her industry knowledge and expertise and such information as he/she is able to obtain in respect of the current market and to provide
his/her determination within 5 days of being requested to do so. The expert's determination shall be final and binding on the parties.

 

	5.2	Such payment shall be made by Medcan by way of EFT to BOPHELO's nominated account
forthwith against presentation by BOPHELO of the relevant invoice to Medcan, which invoice shall be presented to Medcan upon delivery
of the relevant Batch Ex Works.

 

	5.3	Notwithstanding the aforegoing, the parties agree that to the extent that Medcan,
or any of Medcan's associates or subsidiaries, sells a Batch at a price which is more than the Price paid to BOPHELO in terms of section
6.1 in respect of such Batch, Medcan shall forthwith pay to BOPHELO the difference between the price paid by Medcan in terms of section
6.1 and the actual price at which the Batch has been sold by Medcan, the principle being that Medcan is not entitled to the benefit of
any margin on the sale by Medcan of any Batch. Medcan shall at the end of each 3 months for the term of this Agreement provide to BOPHELO
a certificate from Medcan’s auditors confirming the prices at which all Batches obtained from BOPHELO were sold by Medcan.

 

6. National and Local
Cannabis Taxes, Fees and Regulations: BOPHELO shall collect, pay and remit any and all local and national cannabis-related fees (including
but not limited to licensing, renewal and inspection fees due pursuant to the Drugs of Abuse Act of 2008, the Medicines Control and Medical
Devices Control Bill 2018 Act No. 5, and the Drugs of Abuse (Cannabis) Regulations, 2018 Act (collectively, the “Acts”))
and any applicable taxes that are owed on the cannabis and cannabis products cultivated, manufactured, sold and exported by BOPHELO,
or are instituted by the Kingdom of Lesotho at any time. Furthermore, the Parties agree to comply with the Acts and all applicable regulations
set forth by the relevant local and national agencies, including but not limited to the Kingdom of Lesotho’s Ministry of Health
and Social Welfare and the Lesotho Narcotics Bureau.

 

    Page 7 of 14

     

    

 

7. Termination Rights:

 

	(a)	Notwithstanding section 1 of this Agreement, Medcan may terminate this Agreement,
subject to any applicable notice and cure periods set forth below, immediately upon delivery of written notice by Medcan to BOPHELO:

 

(1)        
in the event of an order for the liquidation of BOPHELO, whether voluntarily or involuntarily winding-up of BOPHELO or the placing of
BOPHELO under judicial management or administration and such order has not been dismissed or rescinded within 120 business days after
granting thereof, or the execution by BOPHELO of an assignment for the benefit of its creditors generally;

 

(2)        
for the loss or suspension of BOPHELO’s national and/or local licenses to cultivate, store, supply and/or export cannabis for a period
of more than 60 consecutive days, provided that such loss or suspension has not been occasioned by a breach by Medcan of its obligations
under this Agreement; or

 

(3)         
for the occurrence of a material breach of this Agreement by BOPHELO that remains uncured for 60 days after the date of receipt by BOPHELO
of written notice of the alleged breach, provided that such breach has not been occasioned by a breach by Medcan of its obligations under
this Agreement,

 

in
each instance without prejudice to Medcan’s right to claim damages from BOPHELO, provided however, that where a termination
arising from BOPHELO’s loss of licensure is occasioned by Medcan’s breach of this Agreement as described in section 8(a)(2),
Medcan shall have no remedy.

 

	(b)	Notwithstanding section 1 of this Agreement, BOPHELO may terminate this Agreement, subject to any
                                  applicable notice and cure periods set forth below, immediately upon delivery of written notice by BOPHELO to Medcan:

 

(1)         for the
passing of an extraordinary resolution for the dissolution of the Medcan, in accordance with the Companies Act, Chapter 386 of the laws
of Malta, an involuntary bankruptcy filing against Medcan that has not been dismissed 120 business days after filing, or the execution
by Medcan of an assignment for benefit of creditors;

 

(2)        
for the loss or suspension of any of Medcan’s applicable licenses required to perform its obligations under this Agreement for
a period of more than 60 consecutive days; and

 

 (3)          for the occurrence of a breach of this Agreement, by Medcan that remains uncured for 60 days after the date of receipt by Medcan of written notice of the alleged breach, provided that such breach has not been occasioned by a breach by BOPHELO of its obligations under this Agreement,

 

    Page 8 of 14

     

    

 

in
each instance without prejudice to BOPHELO’s right to claim damages from Medcan. If consequent
upon an unremedied breach by Medcan, BOPHELO elects to terminate this Agreement, BOPHELO shall be entitled to require Medcan, which
shall be obliged to pay to BOPHELO, as a genuine pre-estimate of the liquidated damages which BOPHELO shall be deemed to have
suffered as a result of Medcan’S breach and without prejudice to BOPHELO’S right to recover from Medcan the actual
damages suffered by BOPHELO as a result thereof and its other rights in law or in terms of this Agreement, an amount equal to D as
calculated in accordance with the following forrnula -

 

D = (A-B)
x P

 

where

 

D represents the amount payable;

 

A represents the Specified Volume;

 

B represents the actual volume of Bulk Biomass which Medcan
has purchased from BOPHELO at the date on which the breach occurs; and

 

P represents the then prevailing Price
per gram of Bulk Extract as determined in accordance with section 6.1.

 

Notwithstanding
the aforegoing, the Parties agree that all amounts which BOPHELO realises from selling any stock of Bulk Biomass in its possession as
at the date of termination less the costs incurred in respect thereof, shall be set off against D.

 

8. Effect of Termination or Expiration.

 

All amounts then due and
payable by Medcan to BOPHELO or by BOPHELO to Medcan will be accelerated and immediately become due upon termination or expiration, unless
such termination results from the other's breach of this Agreement and the delivery of payment is at issue as a result of such breach.

 

9. Warranties.

 

Medcan hereby warrants to BOPHELO that Medcan –

 

	9.1	is and will for the duration of this Agreement remain duly registered with all
such regulatory authorities and or bodies and is and will remain in possession for the duration of this Agreement of all such licenses
and other regulatory approvals, as may be required for Medcan to lawfully perform all aspects falling within or being implicit in the
scope of its obligations in terms hereof, including its ability to lawfully purchase the Bulk Biomass from BOPHELO in terms hereof;

 

	9.2	will not act in breach of any law or regulation which it is required to comply with
in performing its obligations in terms hereof;

 

	9.3	 is duly incorporated and validly exists as a company in accordance with the laws
of Malta;

 

	9.4	has the power to enter into, deliver and perform, and has taken
all necessary action to authorise its entry into, delivery and performance of, this Agreement and that its entry into, delivery and performance
of this Agreement does not contravene or conflict with any of its constitutional documents nor any law or regulation or judicial or administrative order which applies to Medcan.

 

BOPHELO hereby warrants to Medcan that BOPHELO –

 

	9.5	is and will for the duration of this Agreement remain duly registered
with all such regulatory authorities and or bodies and is and will remain in possession for the duration of this Agreement of all such
licenses and other regulatory approvals, as may be required for BOPHELO to lawfully perform all aspects falling within or being implicit
in the scope of its obligations in terms hereof, including its ability to lawfully supply the Bulk Extract to Medcan in terms hereof,
including delivery of the Bulk Extract Ex Works for Clearance;

 

    Page 9 of 14

     

    

 

	9.6	will not act in breach of any law or regulation which it is required to comply with
in performing its obligations in terms hereof;

 

	9.7	is duly incorporated and validly exists as a company in accordance with the laws
of the Kingdom of Lesotho;

 

	9.8	has the power to enter into, deliver and perform, and has taken all necessary action
to authorise its entry into, delivery and performance of, this Agreement and that its entry into, delivery and performance of this Agreement
do not contravene or conflict with any of its constitutional documents nor any law or regulation or judicial or administrative order which
applies to BOPHELO.

 

10. Miscellaneous.

 

a)       Time is of the
Essence.

 

The Parties acknowledge and agree that
time is of the essence in performing the obligations set forth in this Agreement.

 

b)       Mediation and
Arbitration.

 

For the purposes of
this section l0(b) a “dispute” shall mean any dispute which arises between the Parties in connection with -

 

		i.	 	the formation or existence;

 

		ii.	 	the implementation;

 

		iii.	 	the interpretation or application of the provisions;

 

		iv.	 	the Parties’ respective rights and obligations in terms
of or arising out of the conclusion, breach or termination;

 

		v.	 	the validity, enforceability, rectification, termination or cancellation, whether in whole or in part;

 

		vi.	 	any documents furnished by the Parties pursuant to the provisions,
of this Agreement or which relates in any way to any matter affecting the interests of the Parties in terms of this Agreement. Save
for those provisions in this Agreement which provide for their own remedies, the Parties agree that any dispute shall, unless resolved
amongst the Parties to the dispute, be referred to and be determined by arbitration.

 

While the Parties
shall attempt amicable conflict resolution and negotiation, the Parties hereto submit to the exclusive jurisdiction of the Malta Arbitration
Centre, of Palazzo Laparelli, 33 South Street, Valletta, VLT 1100, Malta, should such amicable solutions prove fruitless.

 

The Parties hereby confirm that any dispute,
matter or interpretation of the Malta Arbitration Centre shall be final and binding on the Parties and that the arbitral award shall be
final and binding and have the effect of a court order.

 

    Page 10 of 14

     

    

 

The arbitration shall
be heard by an arbitration tribunal which shall consist of 3 arbitrators and in accordance with the procedure laid out in the Malta Arbitration
Act, Chapter 387 of the laws of Malta.

 

c)       Governing Law.

 

This Agreement and
all rights and obligations hereunder, including matters of validity and performance shall be governed and construed in accordance with
the Laws of Malta.

 

d)       Amendments.

 

These terms cannot be
amended, modified or changed in any manner, except by a written amendment designated as such and signed by an authorized
representative of each Party hereto.

 

e)       Independent
Contractor.

 

The relationship between
Medcan and BOPHELO is that of independent contractors. Nothing contained herein shall be construed to create a principal-agent or employer-employee
relationship between the Parties. Neither Party shall represent to others that it is the agent of the other.

 

		f)	Notices.

 

(1) 
The Parties choose domicilium citandi et executandi (“Domicilium”) for all purposes of the giving of any notice, the
payment of any sum, the serving of any process and for any other purpose arising from this Agreement, as follows 

 

BOPHELO:

T’ sakholo, Ha-Mojela

Mafeteng
District

Kingdom of Lesotho

 

Attorneys for BOPHELO

Ira Epstein

Fluxmans Inc

30 Jellicoe Avenue, Rosebank

Johannesburg,
South Africa

iepstein@fluxrnans.com

 

MEDCAN:

Level 4, the Penthouse, Suite 2,

Ewropa Business Centre

Triq Dun Karm

 

Attorneys for Medcan:

Dr. Jonathan Corrieri

Level 4, the Penthouse, Suite 2,

Ewropa Business Centre

Triq Dun Karm

Birkirkara

BKR 9034

Malta

Jonathan@corriericilia.com

 

    Page 11 of 14

     

    

 

		(2)	Each of the Parties shall be entitled from time to time, by written notice to the other, to vary its domicilium
to any other physical address and/or its email address.

 

		(3)	Any notice given and any payment made by any Party (“the sender”) to the other (“the
addressee”) shall be in writing and if -

 

		(i)	delivered by hand during the normal business hours of the addressee at the addressee’s domicilium
for the time being shall be presumed to have been received by the addressee at the time of delivery;

 

		(ii)	delivered by way
                                            of courier service shall be presumed to have been received by the addressee on the 7th
                                            business day following the date on which the courier service was placed in possession
                                            of such notice;

 

		(4)	Any notice given by the sender to the addressee which is transmitted by email to the
addressee at the addressee’s email address, for the time being shall be presumed to have been received by the addressee when (i) the email
enters an information system designated or used
for that purpose by the addressee and is capable of being retrieved by the addressee; and (ii) the sender has received a return email
from the addressee of the email acknowledging receipt by the addressee of that email (it being the responsibility of the sender of that
email to obtain such acknowledgment).

 

		(5)	Notwithstanding
anything to the contrary contained in this section 10(f), written notice or other communication actually
received by a party shall be adequate written notice or communication to it notwithstanding that the notice was not sent or delivered
to its chosen address or email address. 

 

		g)	Severability.

 

In the event that
any one or more of these provisions is held invalid, illegal or unenforceable in any respect by a court with jurisdiction, the validity,
legality and enforceability of the remaining provisions contained herein shall not be in any way impaired thereby. In the event the provisions
of any such applicable law may be waived, they are hereby waived by BOPHELO and Medcan to the full extent permitted by law, and these
terms shall be deemed to be valid, binding and enforceable.

 

h)       Waiver.

 

No
omission or delay by either party at any time to enforce any right or remedy reserved to it, or to require performance of any of the
terms, covenants or provisions hereof at any time designated, shall be a waiver of any such right or remedy to which either Party is
entitled, nor shall it in any way affect the right of either Party to enforce such provisions thereafter. No waiver of any rights or
obligations shall be effective unless in writing and signed by an officer or other authorized representative of the Party holding
such rights or to whom such obligations are owed, and any such waiver shall be effective only in the specific instance and for the
specific purpose stated in such writing.

 

    Page 12 of 14

     

    

 

i)       Survival.

 

All
terms that by their nature would be intended to survive expiration or termination of this Agreement shall so survive, and in
particular, it is expressly agreed by the Parties that the obligations regarding confidentiality shall so survive.

 

j)       No Third-Party
Beneficiaries.

 

All of these terms are for the sole and exclusive benefit
of the Parties.

 

k)       Interpretation.

 

The Parties agree
that the rule of construction that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation
of these terms. Each Party has had the opportunity to consult the legal counsel of its choice. Unless otherwise required by the context
in which the term appears, the words include, includes and including will be deemed to be followed by the phrase “without limitation”
and will not be construed to mean that the examples given are an exclusive list of the topics covered. All defined terms apply to both
singular and plural forms, and all references to any gender include all other genders. The captions are for convenience only, and in no
way limit or amplify the provisions hereof.

 

l)       Integration.

 

These terms constitute
the entire agreement between the Parties in respect of the subject matter hereof and shall replace and supersede all prior and/or contemporaneous
agreements, negotiations or representations between the Parties with respect to the subject matter hereof, whether written or oral. To
the extent there is any inconsistency between these terms and any invoice or similar document produced by Medcan, these terms shall govern.
No subsequent acceptance, acknowledgment or other document submitted by one Party to the other shall vary these terms unless confirmed
in writing by the other Party.

 

m)       Interest.

 

Any amount falling
due for payment by Medcan to BOPHELO in terms of this Agreement shall bear interest at the prime rate, calculated from the due date
for payment (or, in the case of any amount payable by way of damages, with effect from the date upon which those damages are sustained)
to the actual date of payment thereof, both dates inclusive.

 

n)       Confidentiality.

 

The
Parties acknowledge that, as a result of this agreement, information not generally available to members of the public and/or of a
proprietary, confidential or commercially-sensitive nature (“Confidential Information”) may or will be disclosed
to either Party. Accordingly, the Parties irrevocably and unconditionally undertake to maintain all and any Confidential Information
disclosed to and/or obtained in the strictest confidence and not at any time to disclose any such Confidential Information to any
person whatsoever, including (without limitation) to professional advisers, consultants, employees, servants or agents.

 

    Page 13 of 14

     

    

 

This OFF-TAKE AGREEMENT is entered
into on this 3rd day of August, 2020.

 

In WITNESS WHEREOF, the parties have set their hands on the date above
written.

 

	 	BOPHELO:	 
	 	 	 
	 	/s/ Louisa Mojela 	 
	 	Bophelo
    Bio Science and Wellness Pty Ltd	 
	 	 	 
	 	By:
    Louisa Mojela	 
	 	Title:
    Director	 
	 	 	 
	 	MEDCAN:	 
	 	 	 
	 	/s/ Dr. Jonathan Corrieri and /s/ Mr. Michael
    Zammit Taboona	 
	 	Medcan	 
	 	By:
    Dr. Jonathan Corrieri and Mr. Michael Zammit Taboona	 
	 	Title:
    “A” Class Director and “C” Class Director	 

 

    Page 14 of 14Exhibit 10.10

 

Bophelo - Cantourage

 

SERVICE, REFINEMENT AND DISTRIBUTION
AGREEMENT

 

between

 

		1.	Cantourage GmbH,

represented by its CEO Philip Schetter

Heinrich-Mann-Str. 12, 14532 Kleinmachnow,
Germany

 

- hereinafter “CANTOURAGE”
-

 

and

 

		2.	Bophelo Bio Science and Wellness (Pty) Ltd

represented by its Chief Financial
Officer & Director Trevor Scott

Khoabane Mojela, Ha Mojela, Ts’Akholo,
Mafeteng, Lesotho

 

- hereinafter “BOPHELO”
-

 

The terms “CANTOURAGE” and “BOPHELO”
include the respective affiliated companies of CANTOURAGE or BOPHELO pursuant to Sections 15 AktG et seqq. [Aktiengesetz - Stock Corporations
Act]. Those companies in which CANTOURAGE holds a share of at least 50 % are also deemed to be affiliated companies of CANTOURAGE.

 

CANTOURAGE and BOPHELO are hereinafter
respectively designated individually as “Party” and together as “Parties”.

 

     

     

    

 

Bophelo - Cantourage

 

TABLE OF CONTENTS

 

	PREAMBLE	4
	 	 	 
	1.	Definitions	4
	 	 	 
	2.	SCOPE of the AGREEMENT	7
	 	 	 
	3.	Term and termination	7
	 	 	 
	4.	Title and risk of loss	8
	 	 	 
	5.	SERVICES	8
	 	 	 
	6.	CONSIGNMENT STOCK	8
	 	 	 
	7.	REFINEMENT	9
	 	 	 
	8.	BRANDS, LABELLING	9
	 	 	 
	9.	Distribution, sales activities	9
	 	 	 
	10.	Order Fulfilment	10
	 	 	 
	11.	Deliveries	10
	 	 	 
	12.	PRICE, INVOICES	10
	 	 	 
	13.	Release of CONTRACTUAL PRODUCT	11
	 	 	 
	14.	Quality; Inspection	11
	 	 	 
	15.	Warranty	11
	 	 	 
	16.	Analysis costs	12
	 	 	 
	17.	RECALL	12
	 	 	 
	18.	Product liability	13
	 	 	 
	19.	Insurance	13
	 	 	 
	20.	Change management	13
	 	 	 
	21.	Obsolescence	13
	 	 	 
	22.	Provision of materials and assistance by CANTOURAGE	13
	 	 	 
	23.	Intellectual property	13
	 	 	 
	24.	CERTIFICATIONS, PERMISSIONS	13
	 	 	 
	25.	Rights of third parties	14
	 	 	 
	26.	Duties to inform; Inspection rights	14
	 	 	 
	27.	Alliance Committee	14
	 	 	 
	28.	Export/Import regulations	14
	 	 	 
	29.	Confidentiality	16

 

    Page 2 of 53

     

    

 

Bophelo - Cantourage

 

	30.	FORM	16
	 	 	 
	31.	Applicable law	17
	 	 	 
	32.	VENUE	17
	 	 	 
	33.	Integral parts of the AGREEMENT	17
	 	 	 
	34.	Final provisions	18

 

    Page 3 of 53

     

    

 

Bophelo - Cantourage

 

PREAMBLE

 

Whereas

 

		(A)	CANTOURAGE is a Manufacturer and Pharmacy Wholesaler of cannabis
for medicinal use.

 

		(B)	BOPHELO is a producer/cultivator of medicinal cannabis incorporated in the Kingdom of Lesotho with the registration number 2018/62924.

 

		(C)	The Parties intend to establish a cooperation which enables BOPHELO with CANTOURAGE’s assistance to market its products within
the European Union, especially within Germany;

 

Now, the Parties agree to enter into the following

 

SERVICE, REFINEMENT
AND DISTRIBUTION AGREEMENT

 

		1.	Definitions

 

Headings are for reference purposes
only and shall in no way define, limit, construe or describe the scope or extent of an article.

 

The Annexes are integral part of
this Agreement and a reference to this Agreement shall always be interpreted as including the Annexes.

 

Unless the context otherwise requires
words importing one gender include all other genders and words incorporating a verb include the respective noun and the single include
the plural, and vice versa.

 

For the purpose of this Agreement,
the Parties agree on the meaning of the following definitions:

 

		1.1	“AGREEMENT” means this Agreement including its Annexes.

 

		1.2	“ALLIANCE COMMITTEE” shall have the meaning described in Clause 25.

 

		1.3	“AVERAGE SELLING PRICE” means the average of the weighted SELLING PRICES over the RELEVANT PERIOD.

 

		1.4	“BACKGROUND RIGHTS” means all intellectual property rights (in particular industrial property rights, copyrights and comparable
rights, including know-how) held by BOPHELO which are necessary for the manufacture of END PRODUCTS.

 

		1.5	“CONFIDENTIAL INFORMATION” means all information disclosed (whether in writing, orally or by another means and whether
directly or indirectly) with respect to the subject matter hereof by one Party (the “DISCLOSING PARTY”) to the other Party
(the “RECEIVING PARTY”) whether before or after the date of this AGREEMENT including, without limitation, information relating
to the DISCLOSING PARTY’s products, operations, processes, plans or
intentions, product information, know-how, design rights, trade secrets, market opportunities and business affairs.

 

    Page 4 of 53

     

    

 

Bophelo - Cantourage

 

		1.6	“CONSIGNMENT STOCK” means the stock of CONTRACTUAL PRODUCTS and END PRODUCTS established and maintained by CANTOURAGE
for BOPHELO.

 

		1.7	“CONSUMER” is any end user of the END PRODUCTS.

 

		1.8	“CONTRACTUAL PRODUCTS” means the products specified in ANNEX 2.

 

		1.9	“DEFECT” means any deviation of a CONTRACTUAL PRODUCT from the agreed quality.

 

		1.10	“DELIVERY” means the delivery of CONTRACTUAL PRODUCTS in accordance with Incoterms® 2020 DAP at the first port of
entry in Germany.

 

		1.11	“DISTRIBUTOR” means any third party which is supplied with END PRODUCTS and not a CONSUMER.

 

		1.12	“END PRODUCTS” means all CONTRACTUAL PRODUCTS which have been successfully REFINED by CANTOURAGE.

 

		1.13	“FORECAST” shall mean, with respect to any twelve (12) month period, a rolling projection or estimate of the demand for
CONTRACTUAL PRODUCTS during such twelve month period which is updated and amended by CANTOURAGE on a quarterly basis, which approximates,
as nearly as possible, based on information available at the relevant time to CANTOURAGE. For the avoidance of doubt, it is possible that
the amount of CONTRACTUAL PRODUCTS in any given month can equal a zero.

 

		1.14	“FORCE MAJEURE” means any unforeseeable and exceptional occurrence, cause or condition beyond the respective PARTY’s
reasonable control and shall include fire; explosion; flood; earthquake; tsunami; extreme adverse weather conditions; act of God; riot;
war or threat of war; civil commotion; pandemic; change in approval or applicable law; regulation or directive having the force of law;
non-availability, interruptions to or shortage of electricity, fuel or raw materials; failure of a Party’s supplier to supply or
manufacturer to manufacture due to any event or circumstance which would constitute FORCE MAJEURE under this Agreement; and strike, labour
dispute or lock-out. However no occurence, cause or condition shall be considered to be an event of Force Majeure if

 

		(i)	and to the extent the Party seeking to invoke the Force Majeure has caused or contributed to the applicable occurence, cause or condition
by its fault or negligence or has failed to use commercially reasonable efforts to prevent or remedy or mitigate the risks resulting from
such occurence, cause or condition, and so far as possible and within a reasonable time period, remove it;

 

		(ii)	the occurence, cause or condition is the result of a breach of any applicable law by the Party seeking to invoke the Force Majeure;
or

 

    Page 5 of 53

     

    

  

Bophelo - Cantourage

 

		(iii)	the occurence, cause or condition was caused by a lack of funds or other financial cause.

 

		1.15	“FOREGROUND RIGHTS” means all intellectual property rights conceived or developed by either Party or its employees or
agents during the term of, and in connection with, the respective Party’s performance under this Agreement.

 

		1.16	“GACP” means the “Guideline on good agricultural and collection practice for starting materials of herbal origin”
(EMEA/HMPC/246816/2005) issued by the European Medicines Agency, as being amended from time to time.

 

		1.17	“MINIMUM PURCHASE PRICE” means the minimum price to be paid by CANTOURAGE to BOPHELO for the CONTRACTUAL PRODUCTS as further
specified in ANNEX 3.

 

		1.18	“MINIMUM QUANTITY” means the minimum quantity of CONTRACTUAL PRODUCTS and END PRODUCTS stored in the CONSIGNMENT STOCK
which shall be determined by the Parties from time to time.

 

		1.19	“PRICE” means the SELLING PRICE and/or PURCHASE PRICE and/or RAP SERVICE PRICE and/or RAP PLUS SERVICE PRICE and/or AVERAGE
SELLING PRICE and/or MINIMUM PURCHASE PRICE as the case may require.

 

		1.20	“PURCHASE PRICE” means the price for the sale of CONTRACTUAL PRODUCTS by BOPHELO to CANTOURAGE calculated as specified
in ANNEX 3.

 

		1.21	“RELEVANT PERIOD” means a period of every month, the first RELEVANT PERIOD starts on first sale of END PRODUCTS at the
date of payment for the END PRODUCTS.

 

		1.22	“REFINE” or “REFINEMENT” means CANTOURAGE’s activities with regard to the conversion of CONTRACTUAL
PRODUCTS into END PRODUCTS as specified in ANNEX 1.

 

		1.23	“SELLING PRICE” means the prices for the sale of END PRODUCTS by CANTOURAGE to DISTRIBUTORS as specified in ANNEX 3 and
amended by the Parties from time to time.

 

		1.24	“RAP SERVICES” means the mandatory services to be provided by CANTOURAGE as specified in ANNEX 1.

 

		1.25	“RAP PLUS SERVICES” means the optional services to be provided by CANTOURAGE as specified in ANNEX 6 and to the extent
these services have been ordered by BOPHELO and accepted by CANTOURAGE.

 

		1.26	“RAP SERVICE PRICE” means the price to be paid by BOPHELO to CANTOURAGE for the RAP SERVICES as specified in ANNEX 3.

 

		1.27	“RAP PLUS SERVICE PRICE” means the price to be paid by BOPHELO to CANTOURAGE for the RAP PLUS SERVICES as specified in
ANNEX 3.

 

    Page 6 of 53

     

    

 

Bophelo - Cantourage

 

		1.28	“TERRITORY” means the territory of the European Union, especially of the Federal Republic of Germany.

 

		2.	SCOPE of the AGREEMENT

 

		2.1	The object of the AGREEMENT is the provision of the RAP SERVICES, and if agreed, the RAP PLUS SERVICES by CANTOURAGE to BOPHELO, the
REFINEMENT of CONTRACTUAL PRODUCTS by CANTOURAGE for BOPHELO, and distribution of END PRODUCTS within the TERRITORY.

 

		2.2	For that purpose,

 

		2.2.1	CANTOURAGE shall provide the RAP SERVICES and RAP PLUS SERVICES
to BOPHELO,

 

		2.2.2	BOPHELO shall deliver CONTRACTUAL PRODUCTS to the CONSIGNMENT
STOCK,

 

		2.2.3	CANTOURAGE shall REFINE certain quantities of CONTRACTUAL PRODUCTS within the CONSIGNMENT STOCK,

 

		2.2.4	CANTOURAGE shall market and distribute END PRODUCTS within the
TERRITORY.

 

		3.	Term and termination

 

		3.1	This AGREEMENT comes into effect upon signature of both Parties and its initial term shall be 5 years. The term shall be extended
each time for further period of 1 years unless the AGREEMENT has been duly terminated prior to the expiration of the term.

 

		3.2	The notice period for a termination by CANTOURAGE is 60 days and for a termination by BOPHELO 60 days.

 

		3.3	BOPHELO can terminate the AGREEMENT before the initial term expires. CANTOURAGE is not allowed to terminate the AGREEMENT before the
initial term expires.

 

		3.4	The right of termination for good cause remains unaffected. Good cause shall be, inter alia, if (i) CANTOURAGE does not dutifully
provide the RAP SERVICES; or (ii) the REFINEMENT is not carried out in accordance with applicable law; or (iii) the END PRODUCTS
do not conform to specifications as set out in ANNEX 5 for reasons not referring to the CONTRACTUAL PRODUCT. BOPHELO has to notify CANTOURAGE
in writing and provide 30 days to remedy the situation. Afterwards if the situation is not remedied, BOPHELO can terminate the AGREEMENT
with immediate effect subject to all further requirements for a termination for good cause as stipulated by applicable law.

 

		3.5	The termination notice has to be in writing.

 

    Page 7 of 53

     

    

  

Bophelo - Cantourage

 

		4.	Title and risk of loss

 

		4.1	Upon DELIVERY, CANTOURAGE shall become the sole owner of the CONTRACTUAL PRODUCTS. CANTOURAGE shall keep all CONTRACTUAL PRODUCTS
derived therefrom free of liens, security interests and encumbrances.

 

		4.2	Upon DELIVERY, CANTOURAGE will assume the risk of loss of the CONTRACTUAL PRODUCTS. CANTOURAGE assumes the risk of loss of all END
PRODUCTS. CANTOURAGE shall maintain an adequate insurance up to an amount of minimum EUR 1,500,000 to cover such potential losses.

 

		5.	SERVICES

 

		5.1	During the term of this AGREEMENT, CANTOURAGE shall provide to BOPHELO the RAP SERVICES and RAP PLUS SERVICES in accordance with the
due diligence of a professional expert.

 

		5.2	The provision of RAP PLUS SERVICES is conditional upon BOPHELO and CANTOURAGE entering into a separate service agreement further detailing
the respective obligations of either Party.

 

		6.	CONSIGNMENT STOCK

 

		6.1	BOPHELO shall be responsible for the DELIVERY of the CONTRACTUAL PRODUCTS . BOPHELO shall not pay for taxes and duties for the importation.

 

		6.2	CANTOURAGE shall inform BOPHELO in due course whenever the quantity of CONTRACTUAL PRODUCTS and END PRODUCTS stored in the CONSIGNMENT
STOCK falls below the MINIMUM QUANTITY.

 

		6.3	CANTOURAGE shall provide to BOPHELO a FORECAST for the period beginning on 1 January 2022 or beginning no later then three weeks
of recieving the expansion of the narcotics license which ever is the later.

 

No later than ten (10) days
prior to the first day of each subsequent calendar quarter, CANTOURAGE shall deliver to BOPHELO a FORECAST for the period beginning with
the first day of such calendar quarter. FORECASTS are subject to RAP PLUS SERVICES and for informational purposes only. They do not create
any binding obligations on behalf of either PARTY; provided, however, that BOPHELO shall not be required to manufacture and sell to CANTOURAGE
any quantity of CONTRACTUAL PRODUCTS that is unreasonably disproportionate to any FORECAST for the period covered by such FORECAST.

 

		6.4	Upon expiration or termination of this AGREEMENT without cause, CANTOURAGE shall destroy and dispose all remaining CONTRACTUAL PRODUCTS
and END PRODUCTS from the CONSIGNMENT STOCK. BOPHELO shall bear all reasonable costs and expense incurred by CANTOURAGE for the distruction
or disposal up to a maximum amount equaling an average cost
of EUR 0,20 per gram. For each destroyed and disposed END PRODUCT, BOPHELO shall pay to CANTOURAGE the difference between the agreed PURCHASE
PRICE and the AVERAGE SELLING PRICE plus statutory value added tax (if applicable).

 

    Page 8 of 53

     

    

 

Bophelo - Cantourage

 

		6.5	Upon termination of this AGREEMENT for cause, CANTOURAGE shall destroy and dispose all remaining CONTRACTUAL PRODUCTS and END PRODUCTS
from the CONSIGNMENT STOCK at costs and expense of CANTOURAGE. For each detroyed and disposed END PRODUCT, BOPHELO shall pay to CANTOURAGE
only the costs of REFINEMENT.

 

		7.	REFINEMENT

 

		7.1	CANTOURAGE shall REFINE CONTRACTUAL PRODUCTS, which are stored in the CONSIGNMENT STOCK on behalf of BOPHELO in such quantities as
CANTOURAGE considers reasonably necessary in order to meet DISTRIBUTOR’s demands for END PRODUCTS.

 

		7.2	The specifications of the END PRODUCTS are set out in ANNEX 5.

 

		7.3	CANTOURAGE shall within 7 days after receiving the testing results for the END PRODUCTS report to BOPHELO on the REFINEMENT results
and provide BOPHELO with the respective CoA (Certificate of analysis).

 

		7.4	CANTOURAGE shall ensure in its contractual relationship with the DISTRIBUTOR that the ownership of the END PRODUCTS shall only transfer
to the DISTRIBUTOR once the SELLING PRICE is paid in full to CANTOURAGE.

 

		8.	BRANDS, LABELLING

 

CANTOURAGE shall distribute and
sell the END PRODUCTS with the brands and labelling specified in ANNEX 7.

 

		9.	Distribution, sales activities

 

		9.1	CANTOURAGE shall use commercially reasonable efforts to market, distribute and promote the END PRODUCTS within the TERRITORY within
the scope of RAP PLUS SERVICES described under ANNEX 6. CANTOURAGE is obliged to make sure that the DISTRIBUTOR has all the required approvals,
permits and licences to handle the END PRODUCTS.

 

		9.2	The PARTIES shall agree on an ANNUAL MARKETING PLAN that will include at least the sales forecasts and extent of the RAP PLUS SERVICES.
The ANNUAL MARKETING PLAN is subject to RAP PLUS SERVICES and can be amended from time to time by a mutual agreement of the PARTIES.

 

    Page 9 of 53

     

    

 

Bophelo - Cantourage

 

		10.	Order Fulfilment

 

		10.1	Upon respective orders of DISTRIBUTORS, CANTOURAGE shall deliver the ordered END PRODUCTS from the CONSIGNMEMT STOCK to the respective
DISTRIBUTOR.

 

		10.2	For each delivery of END PRODUCTS to the respective DISTRIBUTOR, CANTOURAGE shall invoice to the respective DISTRIBUTORS the respective
SELLING PRICE plus statutory value added tax and costs and expenses.

 

		10.3	In the event a DISTRIBUTOR fails to pay invoiced amounts in a timely manner, CANTOURAGE shall submit at least two payment reminder
notices to the respective DISTRIBUTOR and take commercially reasonable measures to enforce the claim at their own costs.

 

		11.	Deliveries

 

BOPHELO shall effect DELIVERY of
CONTRACTUAL PRODUCTS in a timely manner as agreed between BOPHELO and CANTOURAGE from time to time.

 

		12.	PRICE, INVOICES

 

		12.1	For RAP SERVICES and RAP PLUS SERVICES, BOPHELO shall pay to CANTOURAGE the PRICES at the dates specified in ANNEX 3 plus statutory
value added tax (if applicable).

 

		12.2	For each END PRODUCT delivered to and paid by a DISTRIBUTOR, BOPHELO shall invoice CANTOURAGE and CANTOURAGE shall pay to BOPHELO
the MINIMUM PURCHASE PRICE plus statutory value added tax (if applicable). For the avoidance of doubt, the MINIMUM PURCHASE PRICE and
the PURCHASE PRICE shall not become payable to the extent CANTOURAGE has not received payment of the SELLING PRICE for the respective
END PRODUCTS.

 

For each CONTRACTUAL PRODUCT that
cannot be refined into an END PRODUCT due to loss of the CONTRACTUAL PRODUCT, BOPHELO shall invoice CANTOURAGE and CANTOURAGE shall pay
to BOPHELO the cost price. The same applies in case of loss of the END PRODUCT.

 

		12.3	CANTOURAGE shall not be obliged to make payment if the delivered CONTRACTUAL PRODUCTS contains a DEFECT.

 

		12.4	CANTOURAGE has to calculate the PURCHASE PRICE within 14 days following the end of each RELEVANT PERIOD and notify it to BOPHELO.
In case the PURCHASE PRICE exceeds the MINIMUM PURCHASE PRICE, BOPHELO shall invoice the PURCHASE PRICE minus the already paid MINIMUM
PURCHASE PRICE plus statutory value added tax (if applicable).

 

		12.5	All PRICES are to be paid in Euro and payable within 14 days after receipt of a respective invoice. Either Party may invoice a PRICE
as soon as the PRICE has become payable.

 

    Page 10 of 53

     

    

 

 

Bophelo - Cantourage

 

		12.6	CANTOURAGE shall be entitled to request an adjustment of PRICES if market conditions require a PRICE adjustment.

 

		13.	Release of CONTRACTUAL PRODUCT

 

		13.1	Prior to the first DELIVERY, CANTOURAGE will audit BOPHELO with regard to its GACP compliance, BOPHELO shall only deliver CONTRACTUAL
PRODUCT which has been produced with same production equipment, production materials and production processes at the same production place
as audited by CANTOURAGE.

 

		13.2	Prior to the first DELIVERY, BOPHELO shall, at the request of CANTOURAGE, produce proof of the conformity of the CONTRACTUAL PRODUCTS
with the agreed specification (ANNEX 2) by submitting a CoA (Certificate of analysis) by an independent third party.

 

		13.3	Each change in the production equipment, the production materials, location or processes used for the production of CONTRACTUAL PRODUCTS
(including the production equipment, production materials, location or processes of sub-contractors and sub-suppliers) shall require a
new sign-off. BOPHELO shall inform CANTOURAGE of any forthcoming or impending changes at the earliest possible date. In addition, the
provisions of Clause 19 apply.

 

		14.	Quality; Inspection

 

		14.1	Prior to DELIVERY, BOPHELO shall inspect the quality of the CONTRACTUAL PRODUCTS and ensure that no CONTRACTUAL PRODUCTS containing
a DEFECT are delivered. In addition, BOPHELO shall send CoA (Certificate of analysis) by an independent third party for each delivered
batch to CANTOURAGE.

 

		14.2	CANTOURAGE shall test samples of each shipment of CONTRACTUAL PRODUCTS in due course. The time limit for notifying evident DEFECTS
or any DEFECTS discovered shall be three weeks as from DELIVERY or discovery of the DEFECT.

 

		15.	Warranty

 

		15.1	Each CONTRACTUAL PRODUCT delivered must have the following quality:

 

		15.1.1	The CONTRACTUAL PRODUCT must conform with the specification agreed in this AGREEMENT.

 

		15.1.2	The CONTRACTUAL PRODUCT must conform with the quality of the Certificate of Analysis delivered by BOPHELO.

 

		15.2	With regard to each DEFECT, CANTOURAGE shall be entitled to the statutory warranty rights.

 

		15.3	In deviation from the statutory provisions, CANTOURAGE may, in respect of any CONTRACTUAL PRODUCT containing a DEFECT, at any time
request to send back or destroy the CONTRACTUAL PRODUCT at costs of BOPHELO.

 

    Page 11 of 53

     

    

Bophelo - Cantourage

 

		16.	Analysis costs

 

Without prejudice to all further
claims, CANTOURAGE shall be entitled for each CONTRACTUAL PRODUCT containing a DEFECT to claim fifty (50) % of the effective analysis
costs incurred in connection with the analysis and elimination of the DEFECT and its consequences. BOPHELO shall be enabled to challenge
such test with a retest. If the retest does not confirm the adverse result brought by the previous test, CANTOURAGE will bear hundred
(100) % of the cost of the retest. If the retest does confirm the adverse result brought by the previous test, BOPHELO will bear hundred
(100) % of the cost of both the previous test and the retest. Parties commit to revisit in good faith this provision in case the practicalities
of the first twelve (12) months of shipments prove to make this stipulation an unexpected burden to any of the Parties.

 

		17.	RECALL

 

		17.1	CANTOURAGE shall be entitled to recall END PRODUCTS supplied to DISTRIBUTORS if such a recall is necessary under applicable law.

 

		17.2	In case of a recall caused by the CONTRACTUAL PRODUCTS, BOPHELO shall, without prejudice to all further claims by CANTOURAGE, indemnify
CANTOURAGE for the reasonable costs of all measures taken by CANTOURAGE to eliminate or minimise the risks which have arisen for CANTOURAGE,
unless the recall has arisen out of any breach of the AGREEMENT by CANTOURAGE or any negligence in the sale or promotion of the END PRODUCTS.
These include in particular the following measures:

 

		17.2.1	the notification of known or the public notification of unknown owners of the products;

 

		17.2.2	the removal and transport - including packaging, insurance, temporary storage and customs duties - of the products from the owner
to CANTOURAGE or to the nearest suitable location at which the fault in the products can be rectified, the products disposed of, destroyed,
temporarily stored or replaced;

 

		17.2.3	the disposal or destruction of the products;

 

		17.2.4	the examination of products which demonstrably belong to any series containing a DEFECT at the premises of the owner or at the nearest
suitable location.

 

		17.3	In case a recall is caused by the REFINEMENT or as a condition in the END PRODUCT and not caused by the CONTRACTUAL PRODUCT, CANTOURAGE
shall, without prejudice to all further claims by BOPHELO, indemnify BOPHELO for the reasonable costs of all measures taken by BOPHELO
to eliminate or minimise the risks, which have arisen for BOPHELO.

 

    Page 12 of 53

     

    

Bophelo - Cantourage

 

		18.	Product liability

 

		18.1	Should any product liability claims be asserted against CANTOURAGE which are based on a fault or DEFECT in a CONTRACTUAL PRODUCT,
BOPHELO shall indemnify CANTOURAGE from these claims and from all costs incurred by CANTOURAGE by reason of the claims asserted, including
any costs of legal defence and costs for corrective measures to mitigate the risk.

 

		18.2	Should any product liability claims be asserted against BOPHELO which are based on a fault in an END PRODUCT or caused by REFINEMENT,
CANTOURAGE shall indemnify BOPHELO from these claims and from all costs incurred by BOPHELO by reason of the claims asserted, including
any costs of legal defence and costs for corrective measures to mitigate the risk.

 

		19.	Insurance

 

Either Party shall be obliged to
maintain business liability insurance and extended product liability insurance with coverage of at least EUR 1 (one) million per claim
for damage.

 

		20.	Change management

 

In case of a change in regulation
affecting the distribution of END PRODUCTS within the TERRITORY, the PARTIES shall mutually agree on necessary measures.

 

		21.	Obsolescence

 

PARTIES shall inform each other
at the earliest possible date of any anticipated or impending restrictions concerning manufacture or delivery of the CONTRACTUAL PRODUCTS
or END PRODUCTS.

 

		22.	Provision of materials and assistance by CANTOURAGE

 

CANTOURAGE shall only be obliged
to provide such services, assistance and cooperation if and to the extent explicitly provided in this AGREEMENT.

 

		23.	Intellectual property

 

Any FOREGROUND RIGHTS created by
CANTOURAGE shall be deemed the sole property of CANTOURAGE as they relate exclusively to the END PRODUCTS.

 

		24.	CERTIFICATIONS, PERMISSIONS

 

The Parties
agree that CANTOURAGE alone shall be the sole owner of all certifications or permissions regarding the END PRODUCTS in so far as these
relate exclusively to the END PRODUCTS and the TERRITORY.

 

    Page 13 of 53

     

    

Bophelo - Cantourage

 

		25.	Rights of third parties

 

		25.1	BOPHELO shall be liable for ensuring that no rights of third parties are infringed through the manufacture and supply of CONTRACTUAL
PRODUCTS.

 

		25.2	CANTOURAGE shall be liable for ensuring that no rights of third parties are infringed through the manufacture and supply of END PRODUCTS.

 

		26.	Duties to inform; Inspection rights

 

		26.1	BOPHELO shall without undue delay provide to CANTOURAGE the information required by applicable law relating to the manufacture and
supply of CONTRACTUAL PRODUCTS and also in regard to compliance with the duties of BOPHELO agreed in this AGREEMENT.

 

		26.2	BOPHELO shall be obliged to inform CANTOURAGE at the earliest possible date of pending or announced changes in the manufacturing location
and process, statutory provisions, in particular applicable accident prevention, occupational safety, environment and similar provisions,
the applicable technical standards and the latest recognised rules of science and technology in so far as these concern or may concern
the CONTRACTUAL PRODUCTS.

 

		26.3	Each Party shall be entitled to check the other Party’s compliance with the obligations agreed in this AGREEMENT (Audit). The
audit is to be announced with a reasonable period of advance notice and to be carried out within the usual business hours of the Party.

 

		26.4	BOPHELO shall retain all information, documents and data concerning the manufacture and supply of CONTRACTUAL PRODUCTS for a period
of at least [10] years from the manufacture of the last CONTRACTUAL PRODUCT and deliver the same to CANTOURAGE if required by applicable
law.

 

		27.	Alliance Committee

 

The Parties shall establish an ALLIANCE
COMMITTEE that shall manage the fulfilment of this AGREEMENT, in particular, but not limited to the regulatory matters, supply arrangements,
adoption and implementation of the ANNUAL MARKETING PLAN etc. The ALLIANCE COMMITTEE shall consist of at least one member of each Party
and shall meet at least once a month by teleconference or more regularly as required to fulfil the AGREEMENT.

 

		28.	Export/Import regulations

 

		28.1	BOPHELO must comply at its own cost and expense with all export control, customs and foreign trade regulations applicable in the export
countries for the CONTRACTUAL PRODUCTS and obtain all necessary
permits unless CANTOURAGE or any third party are obliged to apply for such permits.

 

    Page 14 of 53

     

    

Bophelo - Cantourage

 

		28.2	CANTOURAGE must comply at its own cost and expense with all import, customs and foreign trade regulations applicable in Germany and
obtain all necessary permits in Germany. CANTOURAGE shall be solely liable for any damage in case CANTOURAGE does not obtain all necessary
import permits.

 

		28.3	BOPHELO must provide CANTOURAGE in writing as early as possible with all information and data which CANTOURAGE requires for the application
of the import permits - especially the Certificate of Analysis.

 

		28.4	BOPHELO must provide CANTOURAGE in writing upon DELIVERY with all information and data which CANTOURAGE requires for the import /
customs clearance. With each shipment, BOPHELO must send the following documents:

 

		•	Certificate of Analysis

 

		•	Delivery Note with the actual amount of CONTRACTUAL PRODUCT
declared

 

		•	Pro Forma Invoice with the actual amount of CONTRACTUAL PRODUCT
declared

 

		•	Export Permit

 

		28.5	In the case of any changes in the origin and/or of features of the products or services sold to CANTOURAGE and/or the relevant regulations,
BOPHELO must update the information specified in Clause 26.2 or any further information which may have become necessary as early as possible
but no later than two (2) weeks following the date when these changes came into force and in any event prior to the planned DELIVERY
date. BOPHELO shall be liable for all expenses and/or damage suffered by CANTOURAGE by reason of any incorrectness or inaccuracy of the
information provided by the supplier unless BOPHELO was not responsible for the breach of duty.

 

		28.6	Neither Party shall be obliged to perform this Agreement if and in so far as relevant regulations, embargos or any other sanctions
preclude their performance.

 

		28.7	BOPHELO guarantees the security of its own supply chain and observes corresponding legal requirements. BOPHELO undertakes at the request
of CANTOURAGE to provide corresponding proof through certificates or declarations.

 

		28.8	Neither Party shall be responsible for any failure of or delay in performance hereunder which may be due, in whole or in part to any
event of FORCE MAJEURE. The Party claiming the existence of a FORCE MAJEURE event shall use commercially reasonable efforts to resume
performance under this AGREEMENT as soon as possible, and if it has not performed under this AGREEMENT due to a FORCE MAJEURE event for
more than thirty (30) days, the other Party may terminate this AGREEMENT without further cost or liability in addition to any other applicable
termination rights.

 

    Page 15 of 53

     

    

Bophelo - Cantourage

 

		29.	Confidentiality

 

		29.1	During the term of this AGREEMENT and after termination or expiration of this AGREEMENT for any reason, the RECEIVING PARTY:

 

		29.1.1	shall keep the CONFIDENTIAL INFORMATION confidential;

 

		29.1.2	may not disclose the CONFIDENTIAL INFORMATION to another person except with the prior written consent of the DISCLOSING PARTY or in
accordance with Clause 27.2 and 27.3; and

 

		29.1.3	may not use the CONFIDENTIAL INFORMATION for a purpose other than the performance of its obligations under this AGREEMENT.

 

		29.2	During the term of this Agreement or thereafter the RECEIVING PARTY may disclose the CONFIDENTIAL INFORMATION to its employees, sub-contractors
and customers only to the extent that it is reasonably necessary for the purposes of this AGREEMENT.

 

		29.3	The RECEIVING PARTY shall ensure that each recipient is made aware of and complies with all the RECEIVING PARTY’s obligations
of confidentiality under this AGREEMENT as if the recipient was a party to this AGREEMENT.

 

		29.4	Clause 27.1 to 27.3 do not apply to CONFIDENTIAL INFORMATION which:

 

		29.4.1	is at the date of this AGREEMENT or at any time after the date of this AGREEMENT comes into the public domain other than due to breach
of this AGREEMENT by the RECEIVING PARTY;

 

		29.4.2	to the extent such information has to be disclosed by the RECEIVING PARTY to public authorities or courts pursuant to statute or applicable
law rules;

 

		29.4.3	can be shown by the RECEIVING PARTY to have been known by the RECEIVING PARTY before disclosure by the DISCLOSING PARTY to the RECEIVING
PARTY; or

 

		29.4.4	subsequently comes lawfully into the possession of the RECEIVING PARTY from another source not under obligation of confidentiality
to the DISCLOSING PARTY.

 

		30.	FORM

 

		30.1	BOPHELO shall make any legally relevant statement, declaration or notice under this AGREEMENT to Cantourage GmbH, Schloßstr.
112, 12163 Berlin, Germany in text form.

 

		30.2	CANTOURAGE
                                            shall make any legally relevant statement, declaration or notice under this AGREEMENT to
                                            BOPHELO Khoabane Mojela, Ha Mojela, Ts’Akholo, Mafeteng, Lesotho and in parallel to
                                            vidya@akandacorp.com in text form.

 

    Page 16 of 53

     

    

Bophelo - Cantourage

 

		31.	Applicable law

 

This AGREEMENT and the performance of the
same shall be governed exclusively by the law of the Federal Republic of Germany (to the exclusion of its conflict of law provisions).
The application of the United Nations Convention on Contracts for the International Sale of Goods (CISG) is excluded.

 

		32.	VENUE

 

		32.1	The exclusive court venue for all disputes arising from or in connection with this AGREEMENT shall be Hamburg, Germany.

 

		32.2	CANTOURAGE has the right to sue BOPHELO also at its place of general jurisdiction.

 

		33.	Integral parts of the AGREEMENT

 

		33.1	Integral parts of this AGREEMENT are: 

 

Annex 1: RAP SERVICES

 

Annex 2: CONTRACTUAL PRODUCTS

 

Annex 3: PRICES

 

Annex 4: Quality Assurance Agreement

 

Annex 5: END PRODUCTS

 

Annex 6: RAP PLUS SERVICES

 

Annex 7: Brands, Labelling

 

		33.2	In the case of ambiguities or inconsistencies, the integral parts of the AGREEMENT shall apply in the following order of precedence:

 

		33.2.1	Prior-ranking, the text of this AGREEMENT shall apply; thereafter the Annexes in the order of their numbering.

 

		33.2.2	Provisions of higher rank shall have precedence in the case of inconsistencies with provisions of lower rank.

 

		33.2.3	Terms and conditions deviating from this AGREEMENT shall have no validity unless the Parties have agreed the deviation in a contractual
document signed by both sides with express reference to the contrary provisions of this AGREEMENT.

 

		33.2.4	Should inconsistencies or ambiguities arise which cannot be unequivocally dispelled through the foregoing order of priority, BOPHELO
shall be obliged to inform CANTOURAGE in writing without delay.

 

    Page 17 of 53

     

    

Bophelo - Cantourage

 

		34.	Final provisions

 

		34.1	No ancillary agreements have been made.

 

		34.2	In so far as any earlier agreements between the Parties exist in regard to the CONTRACTUAL PRODUCTS and their supply, these agreements
lose their validity upon signature to this AGREEMENT.

 

		34.3	General terms and conditions of either Party shall not apply even if a Party has referred to such terms and conditions.

 

		34.4	This AGREEMENT is executed in duplicate. Each Party hereto receives one signed copy.

 

		34.5	Any amendments or supplements need to be made in written form in order to be effective. This also applies for the revocation or amendment
of the requirement of the written form.

 

		34.6	Should individual provisions of this AGREEMENT be or become ineffective or incapable of performance, either in whole or in part, or
should this AGREEMENT contain any gap in its provisions, the effectiveness of the remaining provisions shall not be thereby affected.
In place of the ineffective provision or provision incapable of performance or for the purpose of filling any gap in the contractual provisions,
such arrangement shall be deemed to be agreed as most closely reflects that which the Parties hereto intended or, in accordance with the
intent and purpose of the AGREEMENT, would have intended had they given consideration to the point.

 

	Berlin, the
    9/15/2021	 	Johannesburg, the 9/15/2021
	 	 	 
	 	 	 
	/s/ Patrick Hoffman	 	/s/ Trevor Scott
	Cantourage GmbH	 	Bophelo Bio Science and Wellness (Pty) Ltd

 

    Page 18 of 53

     

    

Bophelo - Cantourage

 

ANNEX
1

(RAP SERVICES and REFINEMENT)

 

		A.	RAP SERVICES

 

Initial setup to secure an initial Import
Permit

 

Paper Audit:

 

Checking the following documents and comparing
them with own specifications to decide whether BOPHELO; is eligible for the program or not:

 

		•	valid cultivation license
		•	representative certificates of analysis (CoAs)
		•	self-disclosure about products
		•	basic statement on the use of pesticides and fertilizers

 

Audit by Cantourage:

 

		•	Auditing BOPHELO; on site to check the conformity of BOPHELO; with the GACP guidelines (in certain cases with support of qualified
third-party experts)
		•	Using checklists, which are based on the WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants:
	 	 	 

		▪	Quality assurance
		▪	Propagation
		▪	Cultivation
		▪	Harvest
		▪	Primary processing
		▪	Packaging

 

Product Definition:

 

		•	Definition and check of the product quality in consideration of the DAB monography (e.g. heavy metals, microbiology, pesticides)
		•	Working with the guidelines that are also specified by the European medicinal book for herbals & drugs
		•	Checking in the German market whether END PRODUCT name may be used or not and checking the END PRODUCT names for trademark violations

 

Registration:

 

		•	Inclusion of BOPHELO; in the narcotic license and manufacturing authorization
		•	Narcotic registration of all necessary third parties (e.g. logistic providers)
		•	Expanding Cantourage’s BTM-license to include the END PRODUCTS

 

    Page 19 of 53

     

    

Bophelo - Cantourage

 

Product Registration:

 

Registration of various END PRODUCTS including
the product central number (PZN) at the “Informationsstelle für Arzneispezialitäten” (IFA).

 

Import Permit:

 

		•	Applying the Import Permit “Einfuhrgenehmigung” at the “Bundesopiumstelle”
		•	Sending the 2 originals to BOPHELO

 

Export Permit:

 

		•	Helping BOPHELO; with the application and the fulfillment of the export if necessary

 

Manufacturing Process

 

Import Management:

 

		•	Arranging a pickup at a German airport
		•	Fulfillment of all relevant aspects for customs clearance
		•	Responsibility for the CONTRACTUAL PRODUCTS from the German Airport on
		•	Carrying and shipping under GDP conditions, which means that the temperature is between 15-25 degrees, the shipment is always safe &
secure and also traceable at any time

 

Quality Management:

 

As part of the quality management of Cantourage,
the following procedures take place with every import:

 

		•	Incoming goods inspection (transport documentation e.g. temperature)
		•	Comparing quantities with delivery note
		•	Taking a representative sample
		•	Carrying out a quality control of the sample
		•	Checking the client’s certificate of analysis (CoA) with the DAB monography
		•	prompt identification of any defects in accordance with the Agreement

 

Batch Labeling:

 

		•	Creating a label that is conform with the European drug law consisting two parts (product-specific level and presentation of the analysis
certificate)
		•	In other European countries, the label is created in coordination with local representatives of the individual states

 

    Page 20 of 53

     

    

 

 

Bophelo - Cantourage

 

Testing and Release:

 

After the CONTRACTUAL PRODUCT is transformed
to END PRODUCTS, it will be tested and released by Cantourage before it can be sold:

 

		•	Taking a representative sample

		•	Carrying out the quality control

		•	Releasing batch if all quality assurance parameters match

		•	taking all other steps to ensure compliance with EU GMP standards

 

Order & fulfillment

 

Storage of CONTRACTUAL PRODUCTS and END
PRODUCTS:

 

The CONTRACTUAL PRODUCTS and END PRODUCTS
are always stored in an anesthetic warehouse under GMP conditions and the requirements of the relevant German and EU guidelines:

 

		•	Temperature is between 15-25 degrees

		•	Humidity and air quality are continuously monitored

		•	Product is always kept safe & secure

		•	Product is stored on one or more pallets in an assigned storage location

 

Order Management & Fulfillment:

 

To ensure that all processes run smoothly,
Cantourage is setting up an own module in a proven virtual Enterprise resource planning system (ERP system) for BOPHELO:

 

		•	Introducing all CONTRACTUAL PRODUCTS and END PRODUCTS into the system

		•	Handling the entire order acceptance via phone, fax, email and the shop with an experienced team of salespeople

		•	Introducing the entire DISTRIBUTOR data into the ERP in order to do the shipping and the billing with BOPHELO; and our logistic providers

		•	Shipping the END PRODUCT within the TERRITORY under GDP conditions

		•	Fulfilling the entire narcotic documentation within the shipping process

 

Return handling & reclamation:

 

Cantourage does the return handling &
reclamation. Within the process, each complaint is first checked and assessed by Cantourage’s quality assurance.

 

		•	Fulfilling a detailed determination and an evaluation of the cause

		•	Tracking the process and e.g. testing a batch if necessary

		•	Taking care of the narcotic documentation and the physical transport management within the reclamation process

		•	Fulfilling any payments of refunds that might be required

 

    Page 21 of 53

     

    

 

Bophelo - Cantourage

 

Payment Fulfillment:

 

		•	Fulfilling the cash flow management including the posting of the receivable

		•	Checking and posting of incoming payments for the individual orders

		•	Sending out payment reminders within the reminder management when the payment target is exceeded

		•	CANTOURAGE will undertake all necessary measures to ensure payments due for the delivery of END PRODUCTS are paid on time and in full

 

Documentation:

 

		•	Providing monthly KPIs to BOPHELO;

		•	Summarizing the sales and presenting them in Euro amounts and product quantities

		•	Documenting the inventories (incoming and outgoing goods), as well as the gross margin analysis

		•	Sharing monthly documentation with the client, in order to discuss future approaches.

 

		B.	REFINEMENT

 

Product Transformation:

 

Transforming the CONTRACTUAL PRODUCTS into
an END PRODUCT by an EU GMP compliant manufacturer in accordance with the relevant EU guidelines thereby producing EU GMP compliant product
that can be sold as such in Germany and will be palatable and appealing to consumers. The activities CANTOURAGE will undertake to do this
include but are not limited to:

 

		•	Trimming

		•	Post treatment (if necessary)

		•	Drying (if necessary)

		•	Packing

		•	Labeling according to defined manufacturing regulations

		•	Testing and Release

 

In the course of the REFINEMENT there will
be trimming and drying losses as well as retentions and testing provisions that will not be included into the END PRODUCT. Cantourage
will keep a record of these losses and retentions, but also of the yield, and will disclose them to BOPHELO; immediately after the REFINEMENT
process.

 

CANTOURAGE will make the best endeavors to
sell the trimming loses and any profits will be split between the 2 parties as per a normal sale of product outlined in this contract.
At all times, BOPHELO owns the trimming losses and has the right to request CANTOURAGE ship such product to another party at BOPHELOS’s
cost.

 

    Page 22 of 53

     

    

 

Bophelo - Cantourage

 

ANNEX 2 

(CONTRACTUAL PRODUCTS)

 

The CONTRACTUAL PRODUCTS must comply with
the following parameters and specification:

 

	Test Parameter	Test Method	Specification
	Appearance	Organoleptic	Dried plant material, branches of Cannabis flowers
	 	 	(untrimmed) and smaller leaves, without larger leaves
	Colour	Organoleptic	Green, grey-green or brown-green
	Odour	Organoleptic	Characteristic for Cannabis
	Identity
    of present Cannabis flowers	Macroscopic	Presence of female
    flowers according to DAB-Monograph “Cannabis flos” Identity test A:
	 	 	 
	 	 	The female
    blossoms are either whole or have fallen into individual pieces. The bracts and flowers stand closely together and the entire
    flower forms a strongly clinched panicle of approximately 1 to 5 cm in length and width, with the dark green bracts protruding somewhat.
    The light brown to brown pistil and cicatrices are together up to 1 cm in length. The tepals are green to light green and, like the
    bracts, densely covered in yellow-white hairs and covered in resin. The crumbled drug contains fragments of the peduncles, bracts
    and panicle segments as well as individual flowers and floral organs. The individual flowers are approximately 5 to 10 mm
    in length, sometimes with short petioles, and consist of a hood-like, green to light green tepal, the female ovaries of 1 to 2 mm
    in size, which may contain a small brown ovule, and a brown pistil with 2 long, thin cicatrices. The bract fragments are dark
    green to green, the peduncles light green. The bracts and all floral organs, apart from the tepals, are more or less densely
    covered in glandular hairs sticky with excreted resin.
	Health	Organoleptic	No visible sign of diseases or pest contamination
	Foreign Material	Ph.Eur. 2.8.2	< 2 % (m/m)
	Loss on Drying	Ph.Eur. 2.2.32	10-15 % (m/m)
	Total Ash	Ph.Eur. 2.4.16	Max. 20 % (m/m)
	Heavy Metals	Ph.Eur. 2.4.27	Lead: max. 5.0 ppm
	 	 	Mercury: max. 0.1 ppm
	 	 	Cadmium: max. 1.0 ppm
	Pesticides	Ph.Eur. 2.8.13	Comply with Ph.Eur. 2.8.13
	Microbiological Quality	Ph.Eur. 2.6.31	TAMC: max. 2.5 x 106 cfu/g
	 	 	TYMC: max. 2.5 x 105 cfu/g
	 	 	Bile-tolerant Gram negative bacteria: max. 104 cfu/g
	 	 	Escherichia coli: absent in 1 g
	 	 	Salmonella: absent in 25 g
	 	 	Pseudomonas aeruginosa: absent in 1 g
	 	 	Staphylococcus aureus: absent in 1 g
	Total THC content	HPLC acc. to Ph.Eur. 2.2.29	Between 90% and
    110% of the content separately agreed in text form for the specific product
	Total CBD content	HPLC acc. to Ph.Eur. 2.2.29	Between 90% and
    110% of the content separately agreed in text form for the specific product

 

    Page 23 of 53

     

    

 

Bophelo - Cantourage

 

ANNEX 3

(PRICES)

 

		A.	RAP SERVICE PRICE

 

The price for the RAP SERVICE is 420.000
EUR and is payable as followed:

 

		•	20.000 EUR, due 10 days after signing of this Agreement and receipt of a proper invoice

 

		•	200.000 EUR, due 10 days after REFINEMENT and the first sale of END PRODUCTS to a DISTRIBUTOR

 

		•	Upon IPO, Bophelo will issue 200,000 EUR of IPO stock to Cantourage. Stock will be held in escrow until first sale obligation
is met. Equity would vest immediately on that first sales event.

 

		B.	RAP PLUS SERVICE PRICES

 

	PLUS Service	One time fee	Recurring / monthly fee
	Homepage	10.000 € (*)	500 €
	Direct HCP access	10.000 € (*)	500 €
	Listing at wholesales	7.500 € / wholesale (*)	150 € / wholesale
	Info material	10.000
    € (*) / 20.000 € / 40.000 €	Printing costs
	Pharma representatives	5.000 € / pharma rep	7.000 € / pharma rep
	Press announcements	2.000 € + placement costs	-
	Advertisements	Real costs + 15 %	-
	Newsletter	1.750 €	Printing
    and distribution costs
	Education program	20.000 €	500 € / physician
	Patient support	10.000 €	Printing costs
	Social Media	1.500 €	1.000 €
	Launch Event	15.000 €	-

 

(*) These PLUS Service are included in the
price of € 420.000 for the RAP Service.

 

The above given prices are rough estimates,
based on the experience of CANTOURAGE for a basis package. Each final price depends on the extent of a chosen service and the respective
service agreement.

    Page 24 of 53

     

    

 

Bophelo - Cantourage

 

		C.	PURCHASE PRICE

 

The PURCHASE PRICE will be calculated as price
per gram of END PRODUCTS received by REFINEMENT of CONTRACTUAL PRODUCTS and consists out of a 70,0 % share of the AVERAGE SELLING PRICE.
It is calculated as followed:

 

AVERAGE SELLING PRICE
per gram x 70 %

 

PURCHASE PRICE and AVERAGE SELLING PRICE refer
to the resulting weight of END PRODUCTS.

 

The weight of END PRODUCTS as a basis for
the PURCHASE PRICE will be lower than the weight of CONTRACTUAL PRODUCTS, due to trimming and drying losses that occur during the REFINEMENT.
Moreover, CANTOURAGE must withhold a minimum quantity of refined CONTRACTUAL PRODUCTS for testing and retentions that will not be included
into the END PRODUCT.

 

The minimum PURCHASE PRICE that CANTOURAGE
has to pay to BOPHELO for CONTRACTUAL PRODUCTS is 2,80 EUR per gram of the END PRODUCT that was refined from the respective CONTRACTUAL
PRODUCT (“MINIMUM PURCHASE PRICE”).

 

		D.	SELLING PRICE

 

The SELLING PRICE will be set by CANTOURAGE
in its own discretion.

 

    Page 25 of 53

     

    

 

Bophelo - Cantourage

 

ANNEX 4

 

-

 

QUALITY ASSURANCE AGREEMENT

 

Bophelo - Cantourage

 

 

    Page 26 of 53

     

    

 

Bophelo - Cantourage

 

QUALITY ASSURANCE AGREEMENT

 

Production and Quality
Control 

of Medicinal Cannabis
Starting Material

 

(Version 01)

 

	between	Cantourage GmbH

		Heinrich-Mann-Str.12	
	 	14532 Kleinmachnow	 
	 	Germany	 

  

 

– hereinafter referred
to as “Cantourage” –

  

	and	Bophelo Bio Science and Wellness (Pty) Ltd
	 	Khoabane Mojela, Ha Mojela, Ts’Akholo, Mafeteng
	 	Lesotho

  

– hereinafter referred
to as “BOPHELO” –

 

    Page 27 of 53

     

    

 

Bophelo - Cantourage

 

		34.7	Preamble

 

The parties to this Agreement consent that,
due to legal provisions, the quality of Medicinal Cannabis Starting Material must be assured. The corresponding provisions must be obeyed.

 

Against this background, the parties to this
Agreement conclude the following contract which is the basis for all shipments of Cannabis Materials from BOPHELO to Cantourage.

 

The following agreements relate to the quality
part of the business relations between Cantourage and BOPHELO. Arrangements on prices and other commercial terms are
reserved for a separate agreement.

 

Legal Background

 

Cultivation of Cannabis in the country of
origin must be done for medical purposes under governmental control according to articles 23 and 28 paragraph 1 of the Single Convention
on Narcotic Drugs from 1961. Both Germany and Lesotho signed the UN Single Convention on Narcotic Drugs.

 

BOPHELO owns a cultivation license
issued by the responsible authority of Lesotho. BOPHELO will undertake all measures to maintain this license. In the case BOPHELO’s
license will be suspended or withdrawn by the authority, this Quality Assurance Agreement is not or no longer executed.

 

    Page 28 of 53

     

    

 

Bophelo - Cantourage

 

Glossary

 

GACP

 

European “Guideline on Good Agricultural
and Collection Practice for Starting Materials of Herbal Origin” (Doc. Ref. EMEA/HMPC/246816/2005 (20 February 2006)).

 

Manufacture

 

All activities necessary to obtain the contracted
Medicinal Cannabis Material, including propagation, cultivation, harvest, post-harvest processing, packaging, quality control.

 

Manufacturing site

 

Location where BOPHELO carries out
all activities to cultivate and process the contracted Medicinal Cannabis Material as specified in Appendix 1 of this agreement. The cultivation
license is used for the following manufacturing site:

 

Bophelo Bio Science and Wellness
(Pty) Ltd

Ts’Akholo, Mafeteng

Lesotho

 

Production

 

see Manufacture

 

    Page 29 of 53

     

    

 

Bophelo - Cantourage

 

		1	Scope

 

Until further notice, the provisions
of this Agreement apply to all Medicinal Cannabis MaterialsBOPHELO supplies and which are listed in Appendix (1) to this Agreement
together with the agreed specifications.

 

This Quality Assurance Agreement
outlines the responsibilities of Cantourage and BOPHELO with respect to the quality assurance of Medicinal Cannabis Materials
produced and supplied by BOPHELO. The responsibilities of Cantourage and BOPHELO are outlined in Appendix (2). Important
contact persons are listed in Appendix (3).

 

		2	Supplier / manufacturer

 

In case of this agreement, BOPHELO
is the supplier and producer of the Medicinal Cannabis Materials.

 

BOPHELO has reported its
activities to the competent authority under the national requirements and is under survey of this authority.

 

		3	Requirements to the production of Medicinal Cannabis Materials

 

		3.1	BOPHELO is obliged to name the manufacturing site/s of the supplied Medicinal Cannabis Materials.

 

The manufacturing site is:

 

Bophelo Bio Science and Wellness
(Pty) Ltd 

Ts’Akholo, Mafeteng 

Lesotho

 

		3.2	BOPHELO must inform Cantourage about any changes in the manufacturing site or manufacturing procedure that can affect
the quality and safety of the products prior to the first delivery of concerned products.

 

		3.3	BOPHELO ensures that the requirements of the GACP guidelines are fulfilled. BOPHELO will undertake all measures to maintain
this GACP conformity.

 

		3.4	BOPHELO must inform Cantourage about all substances used in the cultivation and processing of the Medicinal Cannabis
Material, especially about all used fertilizer and pesticides. All pesticides used must be approved for use on medicinal plants by both
local and European governments at application levels intended to meet established tolerance levels for the Cannabis.

 

		3.5	BOPHELO ensures that the legislative limits for pesticides and heavy metals as well as the microbiological purity and all other
specifications as defined in Appendix (1) are kept (to be certified in the Certificate of Analysis).

 

		3.6	BOPHELO is obliged to give all information about the Cannabis Material that is or could be necessary to fulfil statutory requirements
(e.g. import licence into the EU) or any information relevant for the European market as requested by Cantourage.

 

    Page 30 of 53

     

    

 

Bophelo - Cantourage

 

		4	Stability data

 

		4.1	BOPHELO provides Cantourage with available stability data related to the contracted Cannabis Material. The primary packaging
material used for stability tests must be identical with the packaging material as defined in Appendix (4).

 

		4.2	Cantourage considers all stability data provided by BOPHELO for the determination of shelf-life and storage conditions
for products for the European market.

 

		5	Packaging / Delivery

 

		5.1	In order to keep the quality of Medicinal Cannabis Materials and the integrity of individual containers, BOPHELO uses suitable
primary and transport packaging systems. Primary packaging materials are agreed between Cantourage and BOPHELO and defined
in Appendix (4).

 

		5.2	BOPHELO will take all measures to avoid any mix-ups or cross-contaminations or microbial contamination during packaging and
labelling. Each single primary container is labelled at least with Material name, batch number, filling weight. Each single transport
container (shipping box) is also labelled at least with Material name, batch number, number of contained primary containers. Mix-ups of
different materials in one transport container should be avoided.

 

		5.3	The following documents must be provided with each delivery:

 

		-	Batch-specific Certificate of Analysis (CoA) showing which parameters have been checked in each batch (including found values and
specified limits) and which have been found on a statistical basis (skip lot testing);

 

		-	Batch-specific Certificate of Manufacture (CoM) according to GACP;

 

		-	a proper delivery note;

 

The delivery is not complete unless
all mentioned documents are available.

 

		5.4	The relevant legal provisions on safety and transport must be observed. Relevant Import Permits must be applied and submitted by Cantourage.
Export permits must be applied and submitted by BOPHELO.

 

		5.5	BOPHELO is responsible for the transport of the Medicinal Cannabis Materials from BOPHELO to Cantourage.

 

		6	Quality Control

 

		6.1	BOPHELO will proceed the quality control according to the agreed specifications and test procedures as defined in Appendix
(1) by using its own laboratory (in-house) and/or a third-party laboratory.

 

		6.2	BOPHELO is responsible for testing the contracted products in accordance with approved validated or qualified methods and specifications
using calibrated equipment. BOPHELO is responsible for having a program for qualification, calibration, and preventive maintenance
of all analytical equipment.

 

		6.3	BOPHELO must ensure that the third-party laboratory has been fully qualified via BOPHELO’s third-party qualification
process prior to performing such activities. BOPHELO shall, however, retain all obligations under this Agreement.

 

		6.3	BOPHELO will inform Cantourage about changes in the testing procedures that can affect the quality and safety of the products prior to
the first delivery of concerned products.

 

    Page 31 of 53

     

    

 

Bophelo - Cantourage

 

		7	Flaw management

 

		7.1	Any visual flaws at incoming deliveries (e.g. outer packaging) are recorded on the delivery note and must be notified to BOPHELO.
The measures to be taken are agreed between BOPHELO and Cantourage on a case-by-case basis.

 

		7.2	If any flaws are discovered afterwards, BOPHELO must be informed immediately. The measures to be taken are also agreed between
BOPHELO and Cantourage on a case-by-case basis.

 

		7.3	Cantourage informs about hidden flaws as soon as they become known.

 

		8	Quality Assurance System

 

		8.1	The quality assurance system applied by BOPHELO bases on the guidelines of GACP and the relevant national legal stipulations.

 

		8.2	BOPHELO will undertake all measures to maintain GACP certification issued by the competent authority.

 

		8.3	BOPHELO allows Cantourage and its representatives or third persons authorised by Cantourage to perform audits
on site to check and evaluate the QA system (audit) and relevant rooms, procedures and equipment, and to look into all the documentations
that relate to the Medicinal Cannabis Materials to be supplied.

 

		9	Deviations and Change Control

 

		9.1	According to its Deviation SOP, BOPHELO categorizes events as Incidents, Deviations and Critical Deviations – depending
on the quality impact on the product and/or patient. BOPHELO will inform Cantourage about Deviations and Critical Deviations
from the specified and agreed manufacturing and testing procedures, product specifications and batch results (OOS) with regard to the
Medicinal Cannabis Materials in writing.

 

The deviation must be evaluated
by BOPHELO with regard to the impact on the product quality and impact on patient safety.

 

		9.2	BOPHELO will inform Cantourage about changes in the manufacturing site, the testing location, the manufacturing and/or
testing procedure as well as the product specification/s of the Medicinal Cannabis Materials to Cantourage in writing. This relates
to changes that can affect the quality and safety of the products. BOPHELO must inform Cantourage about those changes prior
to the first delivery of concerned products.

 

		10	Documentation

 

		10.1	All documents necessary to trace back quality and products of the contracted Medicinal Cannabis Materials should be stored at the
site of BOPHELO, for at least 5 years after releasing the batch.

 

		10.2	The following documents must be provided with each delivery:

 

		-	Batch-specific Certificate of Analysis (CoA) showing which parameters have been checked in each batch (including found values and
specified limits) and which have been found on a statistical basis (skip lot testing);

 

		-	Batch-specific Certificate of Manufacture (CoM) according to GACP;

 

    Page 32 of 53

     

    

 

Bophelo - Cantourage

 

		-	a proper delivery note.

 

		11	Confidentiality

 

	11.1	BOPHELO and Cantourage mutually undertake to observe secrecy on each other’s know-how that became known to them
in the course of this Agreement. This also applies for a period of three years after the co-operation has ended.

 

	11.2	The
obligation of confidentiality and of not using information does not apply if that information

 

		a)	was already known to the other party before its disclosure under the Agreement and the other party declares this fact immediately,
or

 

		b)	has become common property through publication or by other means, or

 

		c)	becomes known to one of the parties without originated directly or indirectly from the other party.

 

		d)	is made available to Authorities due to legal requirements.

 

		12	Term / Termination

 

		12.1	This Agreement shall come into force and effect once signed by the both parties hereby. It shall be concluded for an indefinite period
and may be terminated with due observance of a notice period of six months.

 

		12.2	The right for an extraordinary termination for good cause (e.g. invalidity of GACP conformity) is not affected.

 

		12.3	Each termination must be effected in writing.

 

		13	Miscellaneous

 

		13.1	Amendments and addenda to this Agreement and its appendices shall be invalid unless made in writing.

 

		13.2	Should a provision of this Agreement prove to be invalid either in part or in full or lose its validity at a later date, the validity
of the other provisions shall not be affected. Another appropriate provision shall apply in place of the invalid provision, insofar as
legally permissible, that comes closest in economic terms to what the parties wanted or would have wanted had they been aware of the invalidity
of the provision.

 

		13.3	The defendant’s seat is determined as the place of jurisdiction according to the legal requirement.

 

		13.4	All rights and obligations under this contract will also devolve upon the contract parties’ legal successors.

 

    Page 33 of 53

     

    

 

Bophelo - Cantourage

 

		14	Signatures

 

	Berlin, 15/09/2021	 	Kleinmachnow, 14/09/2021	 
	Place, date	 	Place, date	 
	 	 	 	 
	/s/ Patrick Hoffman	 	/s/ Constanze Pelzer	 
	Signature 	 	Signature 	 
	Cantourage GmbH	 	Cantourage GmbH	 
	Managing Director	 	Qualified Person	 
	 	 	 	 
	Johannesburg, 15/09/2021	 	London, UK 15/09/2021	 
	Place, date	 	Place, date	 
	 	 	 	 
	/s/ Trevor Scott	 	/s/ Dallas Dunkley	 
	Signature	 	Signature	 
	Bophelo Bio Science and Wellness (Pty) Ltd	 	Bophelo Bio Science and Wellness (Pty) Ltd	 
	Managing Director	 	Quality Assurance Manager	 

 

    Page 34 of 53

     

    

 

Bophelo - Cantourage

 

Appendices:

 

		(1)	List of Medicinal Cannabis Products, agreed specifications and test methods

 

		(2)	Quality Responsibilities Table

 

		(3)	List of Contact Persons

 

		(4)	Quality of Primary Packaging Material

 

    Page 35 of 53

     

    

 

Bophelo - Cantourage

 

APPENDIX (1)

 

List of contracted
Medicinal Cannabis Products,

agreed specifications
and test methods

 

(Version 01)

 

To the

QUALITY ASSURANCE AGREEMENT

 

Production and Quality
Control

of Medicinal Cannabis Starting Materials

 

	between	Cantourage GmbH
	 	Heinrich-Mann-Str.12
	 	14532 Kleinmachnow
	 	Germany

 

– hereinafter referred
to as “Cantourage” –

 

	and	Bophelo Bio Science and Wellness (Pty) Ltd
	 	Khoabane Mojela,
	 	Ha Mojela, Ts’Akholo, Mafeteng,
	 	Lesotho

 

– hereinafter referred
to as “BOPHELO” –

 

    Page 36 of 53

     

    

 

Bophelo - Cantourage

 

		1.1.	List of contracted Medicinal Cannabis Products

 

Contracted Medicinal Cannabis Products are
GACP Cannabis Starting Materials of agreed genetics (Cannabis strains).

 

For each single contract product, an individual
specification sheet based on Annex 2 of the Supply Agreement is issued and signed by BOPHELO and submitted to Cantourage.

 

		1.2.	List of agreed specifications and test methods

 

See Annex 2 of the Supply Agreement.

 

For each single contract product, an individual
specification sheet based on Annex 2 of the Supply Agreement is issued and signed by BOPHELO and submitted to Cantourage.

 

		1.3.	History

 

	Version	 	Status	 	Changes of previous version
	01	 	06 / 2020	 	---

 

    Page 37 of 53

     

    

 

Bophelo - Cantourage

 

APPENDIX (2)

 

Quality Responsibilities
Table

 

(Version 01)

 

To the

QUALITY ASSURANCE AGREEMENT

 

Production and Quality
Control

of Medicinal Cannabis Starting Materials

 

	between	Cantourage GmbH
	 	Heinrich-Mann-Str.12
	 	14532 Kleinmachnow
	 	Germany

 

– hereinafter referred
to as “Cantourage” –

 

	and	Bophelo Bio Science and Wellness (Pty) Ltd
	 	Khoabane Mojela,
	 	Ha Mojela, Ts’Akholo, Mafeteng,
	 	Lesotho

 

– hereinafter referred
to as “BOPHELO” –

 

    Page 38 of 53

     

    

 

Bophelo - Cantourage

 

		2.1.	Quality Responsibilities

 

	 	Responsibilities	Cantourage	BOPHELO
	1	Compliance Requirements	 	 
	1.1	Implement
    procedures and/or documented training to meet obligations under this Agreement.	 	x
	1.2	Follow applicable current GACP and locally imposed requirements.	 	x
	1.3	Cultivation, harvesting, drying, packaging, testing, storage in an environment meeting the applicable regulations, which is designed, constructed and maintained in a manner that a) permits the operation therein to be performed under clean, sanitary and orderly conditions; b) permits the effective cleaning of pertinent surfaces; and c) prevents the contamination of Medical Cannabis Starting Materials and the addition of extraneous material on Medical Cannabis Starting Materials.	 	x
	1.4 	Operate in compliance with applicable environmental, occupational health and safety laws and regulations.	 	x 
	1.5 	Maintain a quality unit that is independent of production that fulfils both quality assurance and quality control responsibilities.	 	x 
	1.6 	Involve the quality unit in all quality related matters and have them review and approve all quality critical related documents.	 	x 
	1.7	As it relates to this Quality Agreement, notify the other party of name changes, corporate reorganization, consolidation, merger or acquisition or sale of the party’s company. Notify other party of key personnel changes.	x	x
	1.8	Maintain internal audit program (self-inspection).	x	x
	1.9	Further Processing of the Cannabis Starting Material according GMP Guidelines to receive Medicinal Cannabis Products of a quality as defined by related monographs of the German and European Pharmacopoeia.	x	 
	1.10	Preparation of Product Quality Review according to GMP with regard to any changes to the processes or analytical methods, results of stability monitoring, quality related returns (EU market), complaints, recalls, adequacy of corrective actions.	x	 
	2	Right to Audit	 	 
	2.1	Cantourage has the right to audit BOPHELO ́s facilities and systems and review documents as they relate to the manufacture of Medical Cannabis Starting Materials. Such inspections and document review shall be conducted by Cantourage at a time, date and duration mutually agreeable to BOPHELO and Cantourage.	x	 
	2.2	Cantourage retains the right to conduct reasonable “for cause” audits. Specific goals/scope of the audit, proposed dates and names of the auditors will be agreed upon mutually by Cantourage and BOPHELO.	x	 
	2.3 	Cantourage provides BOPHELO with a confidential audit report summarizing audit observations.	x 	 
	2.4	BOPHELO provides Cantourage with responses to all observations documented in the issued audit report in writing to Cantourage’ Quality Assurance within 30 days of receipt of the report.	 	x

 

    Page 39 of 53

     

    

 

Bophelo - Cantourage

 

	 	Responsibilities	Cantourage	BOPHELO
	3	Regulatory Inspections and Exchanges	 	 
	3.1	Notifies Cantourage within three business days of the receipt of a Regulatory Authority inspection report, deficiency letter or written regulatory compliance observation, which contains any significant adverse findings that relate to Medical Cannabis Starting Materials or the facilities used to produce, test or warehouse Medical Cannabis Starting Materials sold to Cantourage. A significant adverse finding is herein defined as the following: conditions, practices, or processes that adversely affect or may potentially adversely affect product or service quality and/or the rights, safety or well- being of subjects/patients and/or quality and integrity of data, documentation, or other materials or information addressed in the inspection.	 	x 
	4	Complaints	 	 
	4.1	Has written procedures in place to document, investigate, and respond to all quality related complaints.	x	x
	4.2	Assists in investigations as reasonably requested by Cantourage for complaints associated with Medical Cannabis Starting Materials.	 	x
	4.3	Retains complaint investigation records and evaluate trends and severity. Implement corrective and preventive actions as necessary.	 	x
	4.4	Cantourage will evaluate all complaints and respond to the complaining side.	x	 
	5	Qualification/Validation	 	 
	5.1	Follows a written qualification master plan for the facilities, equipment/instruments, and computerized systems as appropriate.	 	x
	5.2	Follows a written validation master plan for related production and testing steps.	 	x
	5.3	Qualify all necessary all critical systems and equipment used for the manufacture and control of the contracted products.	 	x
	5.4	Allow viewing the qualification/validation documentation during an onsite audit.	 	x
	6	Documents and Records	 	 
	6.1	Has a controlled system to initiate, review, revise, approve, obsolete and archive all manufacturing documentation. At a minimum, all production, control, and distribution records should be retained for at least 5 year after the release of the batch.	 	x
	6.2	Has a written procedure for the review and approval of all batch documentation.	 	x
	6.3	Maintain a document control system for specifications and test methods, including product labelling, packaging materials and other materials that would likely affect product quality.	 	x  

 

    Page 40 of 53

     

    

 

Bophelo - Cantourage

 

	 	Responsibilities	Cantourage	BOPHELO
	6.4	Provide a complete Certificate of Analysis for the product,
    containing “at minimum” the following information:	 	x
	 	 	 	 
	 	Name (variety) of the material,	 	 
	 	Batch number,	 	 
	 	Package size,	 	 
	 	Manufacturing site,	 	 
	 	Harvest date,	 	 
	 	Package date,	 	 
	 	Testing site,	 	 
	 	Name of the test,	 	 
	 	Specification limit,	 	 
	 	Test result (as a numerical
    value, unless designated Pass/Fail in the specification limit),	 	 
	 	Testing date,	 	 
	 	Quality Assurance/Control approval and date.	 	 
	6.5	Provides confirmation that the
    Medical Cannabis Starting Material was manufactured (cultivated, harvested, primary processed), packed and tested in accordance with
    GACP requirements, and was tested in accordance with and meets agreed specification.	 	x
	7	Change Control
	7.1	Has established written procedures for
    control of changes impacting the product.	x	x
	7.2	Notifies Cantourage within a reasonable
    time about changes that can affect the quality and safety of the products (called significant).	 	x
	7.3	Has significant changes reviewed and approved by its quality unit.	 	x
	8	Deviations/OOS
	8.1	Has procedures for the identification,
    investigation of deviations and Out-of-Specification (OOS) results that occur during the manufacture and testing of Medical Cannabis Starting Materials.	 	x
	8.2	Documents and explains all deviation.
    Investigates OOS results and critical deviations.	 	x
	8.3	Notifies Cantourage within a reasonable
    time about Major and Critical deviations. Deviations are categorized as Minor, Major and Critical (depending on the quality impact
    on the product) according to BOPHELOs deviation SOP.	 	x
	9	Production and In-Process Controls, Packaging and Labelling
	9.1	Procures, tests as required, and
    releases packaging and labelling materials used in manufacture of the contracted products.	 	x
	9.2	Defines specifications for product
    labelling and packaging materials and other materials that would likely affect product quality.	x	 
	9.3	Establish and document specifications
    for product labelling and packaging materials and other materials that would likely affect product quality.	 	x
	9.4	Manufactures the contracted Cannabis
    Starting Materials in a manner that prevents contamination by other materials including carryovers.	 	x
	9.5	Records all production steps and related
    in-process controls in a Batch Record.	 	x
	9.6	Releases Medical Cannabis Starting Materials by its quality unit.	 	x

 

    Page 41 of 53

     

    

 

Bophelo - Cantourage

 

	 	Responsibilities	Cantourage	BOPHELO
	10	Storage and Distribution
	10.1	Maintains storage facilities appropriate for conditions having no negative impact on the
    quality and integrity of the Medicinal Cannabis Starting Materials. Maintain records of any critical storage conditions.	 	x
	10.2	Has systems for controlling quarantined, rejected or recalled materials.	 	x
	10.3	Notifies Cantourage in a timely manner in the case of finding a quality issue post release/shipment.	 	x
	10.4	Organization and realization of transport of the contracted materials to the responsible custom site in Germany (Airport Berlin Tegel).	 	X
	10.5	Organization and realization of transport of the contracted materials after customs clearance to the contracted storage partner in Germany.	x	 
	11	Laboratory Controls
	11.1	Has a written procedure for sample management, testing, approval, disposition, recording, storage, retention and disposal of laboratory data.	 	x
	11.2	Retains samples of the Cannabis Starting Materials as required by regulatory agencies.	x	x
	11.3	Has written procedures and appropriately document the preparation, use and management of
    reagents, solutions, and standards for testing the Cannabis Starting Materials.	 	x
	11.4	Defines release specifications for Medicinal Cannabis Starting Materials.	x	 
	11.5	Responsible for having appropriate test procedures for Medical Cannabis Starting Materials.	 	x
	11.6	Responsible for testing the contracted materials in accordance with approved validated or
    qualified methods and specifications using calibrated equipment.	 	x
	11.7	Responsible for the third party laboratory testing Medical Cannabis Starting Materials in
    accordance with approved validated or qualified methods and specifications using calibrated equipment.	 	x
	11.8	Responsible for having a program for qualification, calibration, and preventive maintenance of all analytical equipment.	 	x
	11.9	Responsible for the third party laboratory having a program for qualification, calibration, and preventive maintenance of all analytical equipment.	 	x
	11.10	Responsible for analytical method development, qualification and/or validation as appropriate.	 	x
	12	Recalls
	12.1	In the event that either Cantourage or BOPHELO determines an event or circumstances has
    occurred relating to the manufacture, testing or stability of the contracted materials which may result in the need for a recall,
    stock recovery or market withdrawal, BOPHELO and Cantourage shall consult with each other in a timely manner. The final decision to
    recall products from the European market shall be made by Cantourage.	x	x
	12.2	Notification of the recall or similar action to the competent authorities and customers in Europe.	x	 
	12.3	Notification of the recall or similar action to the competent authorities and customers in Lesotho.	 	x

 

    Page 42 of 53

     

    

 

Bophelo - Cantourage

 

		2.2.	History

 

	Version	Status	Changes of previous version
	01	06 / 2020	---

 

    Page 43 of 53

     

    

 

Bophelo - Cantourage

 

APPENDIX (3) 

 

List of Contact Persons

 

(Version 01)

 

To the 

QUALITY ASSURANCE AGREEMENT

 

Production and Quality
Control 

of Medicinal Cannabis
Starting Material

 

	between	Cantourage GmbH
	 	Heinrich-Mann-Str.12
	 	14532 Kleinmachnow
	 	Germany

 

– hereinafter referred
to as “Cantourage” –

 

	and	Bophelo Bio Science and Wellness (Pty) Ltd
	 	Khoabane Mojela,
	 	Ha Mojela, Ts’Akholo,
Mafeteng,
	 	Lesotho

  

– hereinafter referred
to as “BOPHELO” –

 

    Page 44 of 53

     

    

 

Bophelo - Cantourage

 

		3.1.	List of Contact Persons at Cantourage

 

	Function	Name	Contact Data
	Managing Director	Philip Schetter	schetter@cantourage.com
	Qualified Person	Constanze Pelzer	pelzer@cantourage.com
	Head of Quality Assurance	Constanze Pelzer	pelzer@cantourage.com
	Head of Quality Control	Constanze Pelzer	pelzer@cantourage.com
	Head of Sales	Bernhard Retzer	retzer@cantourage.com

 

		3.2.	List of Contact Persons at BOPHELO

 

	Function	Name	Contact Data
	CEO	Tej Virk	tej@akandacorp.com
	Quality Assurance Manager	Dallas Dunkley	dallas@akandacorp.com
	CFO	Trevor Scott	trevor@akandacorp.com

 

		3.3.	History

 

	Version	Status	Changes of previous version
	01	06 / 2020	---

 

    Page 45 of 53

     

    

 

Bophelo - Cantourage

 

APPENDIX (4) 

 

Quality of Primary
Packaging Material

 

(Version 01)

 

To the

QUALITY ASSURANCE AGREEMENT

 

Production and Quality
Control 

of Medicinal Cannabis
Starting Material

 

	between	Cantourage GmbH
	 	Heinrich-Mann-Str.12
	 	14532 Kleinmachnow
	 	Germany

  

– hereinafter referred
to as “Cantourage” –

 

	and	Bophelo Bio Science and Wellness (Pty) Ltd
	 	Khoabane Mojela,
	 	Ha Mojela, Ts’Akholo,
Mafeteng,
	 	Lesotho

 

– hereinafter referred
to as “BOPHELO” –

 

    Page 46 of 53

     

    

 

Bophelo - Cantourage

 

4.1. Quality of Primary Packaging Material

 

Cannabis Starting Material

 

	Part of Packaging System	Material	Quality
	Aluminium Foil Bag	Aluminium composite film

(e.g. PET/ALU/PE)	The product touching layer consists of Polyethylene (PE) and
    complies with Regulation (EU) 10/2011 incl. all changes and corrections.

 

		4.2.	History

 

	Version	Status	Changes of previous version
	01	06 / 2020	---

 

    Page 47 of 53

     

    

 

Bophelo - Cantourage

 

ANNEX 5 

(END PRODUCTS)

 

Bulk Sizes

 

To be determined between both PARTIES following
the conclusion of the contract.

 

Specification

 

	 	Method	Specification
	Characteristics	DAB Cannabis flos (Characteristics)	Characteristic smell
	Identity
	appearance	DAB Cannabis flos (Identity A)	Comply with monograph
	microscopy	DAB Cannabis flos (Identity B)	Comply with monograph
	thin
    layer chromatography	DAB Cannabis flos (Identity C), Ph.Eur. 2.2.27	Comply with monograph
	Purity
	Foreign material	DAB Cannabis flos / Ph.Eur. 2.8.2	Max. 2 % (m/m)
	Loss on Drying	DAB Cannabis flos / Ph.Eur. 2.2.32	Max. 10 %
	Pesticides	Ph.Eur. 2.8.13	Comply with Ph.Eur. 2.8.13
	Absence of heavy metals	Ph.Eur. 2.4.27	 
	Lead	 	Max. 5.0 ppm
	Mercury	 	Max. 0.1 ppm
	Cadmium	 	Max. 1.0 ppm
	Aflatoxin B1	Ph.Eur. 2.8.18	≤ 2 ppb
	Total Ash	Ph.Eur. 2.4.16	Max. 20 %
	Microbiological purity	Ph.Eur. 2.6.31	Comply with Ph.Eur. 5.1.8 C
	Total
    aerobic microbial count (TAMC)	 	Max. 500.000 cfu/gram
	Total
    yeast and molds count (TYMC)	 	Max. 50.000 cfu/gram
	Bile-
    tolerant Gram negative bacteria	 	≤ 104 cfu/gram
	E. coli	 	Absent in 1 g
	Salmonella	 	Absent in 25 g
	Related substance	DAB Cannabis flos / Ph.Eur. 2.2.29	 
	Cannabinol (CBN)	 	≤ 1.0 %
	Assay
	Dronabinol (THC)	DAB Cannabis flos / Ph.Eur. 2.2.29	Depends on product (to be defined for each product)
	Cannabidiol (CBD)	 	Depends on product (to be defined for each product)

 

    Page 48 of 53

     

    

 

Bophelo - Cantourage

 

ANNEX 6

(RAP PLUS SERVICES)

 

Homepage:

 

Creating a Homepage (English and German)
that complies the legal regulations of Germany and Europe.

 

Content:

 

		-	Landing Page: Background picture or animation, Company Slogan, Logo

		-	About: Company description, Company Backstory, Particularities

		-	Team: Introductions of Board and Staff members

		-	Product Information (not allowed for medical Cannabis, Extracts or substantives because of advertising ban – see DocCheck)

		-	Press: latest Press releases, Contact information of PR manager

		-	News: constant uploads of company and market news

		-	FAQ: frequently asked questions

		-	Contact us: Contact Data and possibility for visitors to leave a direct message.

		-	Terms and Conditions (mandatory)

		-	Privacy Policy (mandatory)

		-	Social Media links

		-	Newsletter sign up

 

DocCheck:

 

Special section on the Homepage with
restricted access for physicians and pharmacists only. It provides detailed information about products for target audience.

 

Listing at Wholesales:

 

An alternative sales channel to direct sales
to pharmacies; in Germany. Cantourage will select appropriate wholesalers and will negotiate standard agreements with them. This includes
the terms of contract, translation of contracts, stockpiling, retour handling.

 

Pharma Representatives:

 

Selection and Employment of suitable Pharma
Representatives

 

		-	Cantourage makes a suggestion of suitable representatives

		-	Cantourage educates and guides those representatives about END
PRODUCTS and BOPHELO’s philosophy

 

Tasks of Pharma Representative:

 

		-	Advice and support for physicians of relevant specialization
in a result-oriented manner

		-	Specialization: General practitioner, Neurologists, pain therapists,
gastroenterologists, palliative care physicians

		-	Taking care of opinion makers

		-	Competent explanation and communication of complex medical matters

 

    Page 49 of 53

     

    

 

Bophelo - Cantourage

 

		-	Well informed about product portfolio

		-	Submission of samples and information material

		-	Operating according to achievement of goals

		-	Independent area management and building customer relationships

		-	Implementation of specified communication and product strategies
and the further development of those

		-	Evaluation of market data (observation of market and competitive
developments)

		-	Regular reporting

		-	Participation in congresses, trainings, and further education

 

Qualification and Profile of our Pharma Representatives:

 

		-	Certified pharmaceutical representative in accordance with §
75 AMG

		-	Most of your Representatives have several years of experience

		-	Already existing network of physicians and pharmacists

		-	Marketing and sales-oriented way of thinking and working

		-	Well-versed in common office software

		-	Excellent command of German and English

 

Education Program:

 

Event for physicians and pharmacists about
medical cannabis

 

		-	Elaborate education program

		-	Placing products as one alternative treatment option

		-	Case studies of patients and treatments

		-	Being named as sponsor for a training event

		-	Having a stand close to the event premises

 

Press announcements:

 

		-	Drafting of press announcement in accordance with local law
and alignment with BOPHELO

		-	Selection of targeted group of recipients (few hundreds to thousands)
of relevant press, especially in medicinal field.

		-	Analysis of spread/success

		-	Follow up on requests and alignment with BOPHELO (e.g. interviews,
stories on client company etc.)

		-	Following announcements for additional products or similar updates

 

Press announcement in German and in English
and client national language

 

    Page 50 of 53

     

    

 

Bophelo - Cantourage

 

Info material:

 

Professional information material for physicians
and pharmacists on END PRODUCT details

 

		-	Generating a small brochure with the necessary information about all END PRODUCTS

		-	Generating a big brochure with all information and details about END PRODUCTS, company and other relevant information

		-	Creating product flyers for physicians and pharmacists

		-	Compilation of a welcome book

 

Newsletter:

 

Monthly newsletter on company and product news

 

		-	 Monthly newsletter with all company and product updates

		-	 Weekly newsletter with all company and product news

		-	Translating existing Newsletter in German or English

 

Advertisement in Journals:

 

Spreading product and company information
through physician and pharmacist magazines and journals

 

		-	Half page Article

		-	Full page article

		-	Small advertisement

		-	Big advertisement

 

Social Media:

 

		-	Translating existing social media posts

		-	Creating Post on existing accounts for
	 	 	 

		o	LinkedIn

		o	Instagram

		o	Facebook

		o	Twitter

 

		-	Creating Accounts “Europe”-Accounts on
	 	 	 

		o	LinkedIn

		o	Instagram

		o	Facebook

		o	Twitter
	 	 	 

		▪	Uploading Posts monthly

		▪	Uploading Posts weekly

		▪	Uploading Posts daily

 

    Page 51 of 53

     

    

 

Bophelo - Cantourage

 

Brand protection:

 

We register BOPHELO’s brands name and
protect it against misuse by third parties.

 

		-	Protection of the company name in Germany

		-	Protection of the company name throughout Europe

 

Release Event

 

		-	Get together with important and influential guest of the German medical cannabis industry (high prescribers, pharmacists and influencers).
Cantourage organizes the whole event management incl. (location, invitations, entertainment program, drinks, snacks, etc.)

 

    Page 52 of 53

     

    

 

Bophelo - Cantourage

 

ANNEX 7 

(BRANDS, LABELLING)

 

To be determined by Bophelo
following the conclusion of the contract.

 

    Page 53 of 53

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]